[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 151
1. Labrie F: [Keyrole of endocrinology in the victory against prostate cancer]. Bull Cancer; 2006 Sep;93(9):949-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Keyrole of endocrinology in the victory against prostate cancer].
  • [Transliterated title] Rôle clé de l'endocrinologie dans la victoire contre le cancer de la prostate.
  • The most significant discovery of the last quarter of the XXth century in the field of prostate cancer is probably the observation that the human prostate synthesizes locally an amount of androgens from the inactive steroid precursors dehydroepiandrosterone (DHEA) and its sulfate DHEA-S that is approximately equivalent to the androgens made in the testis.
  • This treatment, called combined androgen blockade, has been the first treatment demonstrated to prolong life in prostate cancer in prospective and randomized studies.
  • While the first studies were performed in patients with advanced and metastatic disease, our recent data indicate a much higher efficacy of the same treatment applied to localized prostate cancer, thus leading to an at least 90 % possibility of cure.
  • In fact, the lifesaving benefits of androgen blockade in prostate cancer have been largely underestimated.
  • When compared to other cancer therapies, the results obtained are quite remarkable.
  • In fact, while death rates decreased by 1.1 % per year from 1993 to 2001 for all cancers combined, prostate cancer showed a larger decrease at 3.6 %.
  • Lichtenberg using National Cancer Institute data obtained from 2.1 million cancer patients, has concluded that "cancer-fighting drugs improved survival rates, especially for cancer of the prostate, where drug innovations have been the greatest".
  • The knowledge about the absence of development of resistance to androgen blockade in localized prostate cancer is extremely important.
  • In fact, it is often erroneously believed that androgen blockade should not be administered early because resistance to treatment will develop and one might as well wait to use androgen blockade at a later stage of the disease.
  • In fact, deferring treatment implies that, very often, it will then be too late, because after the cancer has migrated to the bones, resistance to treatment can no more be avoided.
  • It should be realized that when prostate cancer is first detected, even by screening, the cancer is not small since its diameter is of the order of 1 cm or more.
  • With the presently available techniques, screening can diagnose prostate cancer at a clinically localized stage in 99 % of cases.
  • Such an early diagnosis permits immediate treatment with a curative intent, combined androgen blockade (CAB) being a truly efficient alternative especially in older patients.
  • Using this strategy, based upon today's available diagnostic and therapeutic approaches, death from prostate cancer can be an exception, confirming that victory against prostate cancer is achieved.
  • [MeSH-minor] Adrenal Glands / metabolism. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Dehydroepiandrosterone / antagonists & inhibitors. Dehydroepiandrosterone / metabolism. Flutamide / therapeutic use. Humans. Male. Orchiectomy. Prostatectomy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980238.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone; 459AG36T1B / Dehydroepiandrosterone; 76W6J0943E / Flutamide
  • [Number-of-references] 30
  •  go-up   go-down


2. Gauger J, Patz EF Jr, Coleman RE, Herndon JE 2nd: Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. J Thorac Oncol; 2007 Jun;2(6):499-505
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.
  • INTRODUCTION: Positron emission tomography (PET) has improved the accuracy of staging non-small cell lung cancer (NSCLC), although some early-stage patients will still relapse.
  • The purpose of this study was to determine the sites and time to recurrence in patients with clinical stage I NSCLC whose initial staging evaluation included conventional imaging and fluorodeoxyglucose-PET.
  • We retrospectively searched our PET database and identified 231 patients (125 women, 106 men; ages 36-93 years) with primary NSCLC and clinical stage I disease.
  • RESULTS: Of the 231 patients with clinical stage I tumors, 196 patients (85%) had pathological stage I disease.
  • Two patients developed a second primary lung cancer, and 40 patients (20%) developed local or distant recurrence.
  • The most common site of first recurrence was the thorax, followed by the brain, bone, and adrenal glands.
  • CONCLUSIONS: Twenty percent of stage I NSCLC patients staged with conventional imaging and PET will develop recurrent NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Neoplasm Recurrence, Local / pathology. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545844.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


3. Pan ZQ, Fang ZQ, Lu WL, Liang C, Wu ZH, Liu XM, Hou L, Zhang H, Zhuo SY, Liao MJ, Gao BF: [Differentially expressed genes in adrenal gland of H22 liver cancer mice with different syndromes and in different stages]. Zhong Xi Yi Jie He Xue Bao; 2008 Aug;6(8):843-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differentially expressed genes in adrenal gland of H22 liver cancer mice with different syndromes and in different stages].
  • OBJECTIVE: To reveal the characteristics of gene expression in adrenal gland of H22 tumor mice with typical syndromes and in different liver cancer stages.
  • METHODS: By the quantitative four diagnosis and syndrome differentiation methods and GeneChip Mouse Exon 1.0 ST Array, we observed adrenal gland gene expression in H22 tumor mice with pathogenic factor-toxin predominance syndrome and qi deficiency syndrome in the earlier stage, yang-qi deficiency syndrome in the intermediate stage, and qi-yin-yang deficiency syndrome in the advanced stage.
  • CONCLUSION: With the development of the tumorigenesis, the symptoms and signs and differentially expressed genes in adrenal gland of H22 tumor mice can be measured.
  • Up-regulated and down-regulated coincident genes may be the features of H22 tumor mice different from those of normal mice.
  • [MeSH-major] Adrenal Glands / metabolism. Diagnosis, Differential. Gene Expression Profiling. Liver Neoplasms, Experimental / genetics. Medicine, Chinese Traditional


Advertisement
4. Loechner KJ, McLaughlin JT, Calikoglu AS: Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises. Int J Pediatr Endocrinol; 2010;2010:670960

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises.
  • Despite decades of different treatment algorithms, the management of congenital adrenal hyperplasia (CAH) remains clinically challenging.
  • This is due to the inherent difficulty of suppressing adrenal androgen production using near physiological dosing of glucocorticoids (GC).
  • Gene therapy and stem cells, to provide functional adrenal cortical tissue, are at preclinical stage but provide exciting avenues for a potential cure for CAH.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Dev. 2010;17:36-43 [19955754.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1114-20 [10720048.001]
  • [Cites] J Pediatr Endocrinol Metab. 2010 Jan-Feb;23(1-2):179-87 [20432821.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1481-8 [20159824.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1496-501 [20159814.001]
  • [Cites] Endokrynol Pol. 2010 Jan-Feb;61(1):126-34 [20205115.001]
  • [Cites] J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S336-44 [20061008.001]
  • [Cites] Harefuah. 2009 Dec;148(12):825-30, 855 [20088436.001]
  • [Cites] J Clin Invest. 2010 Jan;120(1):51-9 [20051636.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Jan;95(1):167-77 [19906787.001]
  • [Cites] Expert Opin Emerg Drugs. 2009 Dec;14(4):661-71 [19939210.001]
  • [Cites] Endocr Rev. 2009 Jun;30(4):343-75 [19389994.001]
  • [Cites] Mini Rev Med Chem. 2009 Sep;9(10):1191-201 [19817711.001]
  • [Cites] Lancet Oncol. 2009 Oct;10(10):981-91 [19796750.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Sep;94(9):3477-80 [19567522.001]
  • [Cites] Hum Reprod Update. 2008 Nov-Dec;14(6):571-82 [18812422.001]
  • [Cites] Pediatrics. 2008 Apr;121(4):e975-83 [18381525.001]
  • [Cites] Eur J Pharmacol. 2008 Apr 7;583(2-3):350-7 [18272149.001]
  • [Cites] Can Fam Physician. 2008 Mar;54(3):353-4 [18337526.001]
  • [Cites] Pediatr Endocrinol Rev. 2008 Feb;5 Suppl 2:744-9 [18317446.001]
  • [Cites] Obstet Gynecol Surv. 2008 Mar;63(3):163-81 [18279543.001]
  • [Cites] J Pediatr (Rio J). 2007 Nov;83(5 Suppl):S172-7 [17901908.001]
  • [Cites] J Endourol. 2007 Sep;21(9):1053-8 [17941786.001]
  • [Cites] Eur J Endocrinol. 2007 Jul;157(1):109-12 [17609409.001]
  • [Cites] Expert Opin Pharmacother. 2007 Apr;8(6):725-9 [17425469.001]
  • [Cites] Mol Cell Endocrinol. 2007 Feb;265-266:10-6 [17240045.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Oct;19(10):1251-5 [17172087.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):689-706 [16954425.001]
  • [Cites] Endocr J. 2006 Aug;53(4):449-59 [16807499.001]
  • [Cites] Ann Pharmacother. 2006 Sep;40(9):1572-83 [16912252.001]
  • [Cites] Mol Cell Endocrinol. 2006 Jul 25;254-255:207-16 [16766117.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4104-11 [16728492.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Jul;65(1):45-50 [16817818.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 May;64(5):510-3 [16649968.001]
  • [Cites] Eur J Endocrinol. 2006 Mar;154(3):405-8 [16498053.001]
  • [Cites] Indian J Pediatr. 2006 Jan;73(1):89-93 [16444069.001]
  • [Cites] Treat Endocrinol. 2004;3(3):141-51 [16026110.001]
  • [Cites] Lancet. 2005 Jun 18-24;365(9477):2125-36 [15964450.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3318-25 [15797962.001]
  • [Cites] J Pediatr Endocrinol Metab. 2005 Jan;18(1):97-101 [15679075.001]
  • [Cites] Horm Res. 2004;62(6):300-5 [15557761.001]
  • [Cites] Genes Cells. 2004 Dec;9(12):1239-47 [15569155.001]
  • [Cites] Pediatr Res. 1999 Sep;46(3):269-73 [10473040.001]
  • [Cites] Steroids. 1999 Jun;64(6):404-12 [10433177.001]
  • [Cites] Endocrinology. 1998 Apr;139(4):1546-55 [9528933.001]
  • [Cites] J Med Chem. 1998 Dec 3;41(25):5012-9 [9836619.001]
  • [Cites] Endocrinology. 1999 Jan;140(1):79-86 [9886810.001]
  • [Cites] Arch Dis Child. 1998 Mar;78(3):261-3 [9613359.001]
  • [Cites] J Pediatr Endocrinol Metab. 1997 Nov-Dec;10(6):623-8 [9467133.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):3926-9 [9398689.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3324-7 [9329362.001]
  • [Cites] Metabolism. 1997 May;46(5):513-7 [9160816.001]
  • [Cites] Neuroimmunomodulation. 1996 Sep-Oct;3(5):259-84 [9218248.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Dec;45(6):707-13 [9039336.001]
  • [Cites] Endocrinology. 1996 Apr;137(4):1429-37 [8625921.001]
  • [Cites] N Z Med J. 1995 Aug 11;108(1005):311-4 [7644165.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jul;80(7):2238-43 [7608286.001]
  • [Cites] J Steroid Biochem Mol Biol. 1994 Sep;50(5-6):267-73 [7918112.001]
  • [Cites] Endocrinology. 1994 Oct;135(4):1470-6 [7925109.001]
  • [Cites] Indian J Pediatr. 1994 Jul-Aug;61(4):341-6 [8002061.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Sep;77(3):647-51 [8370686.001]
  • [Cites] Am J Dis Child. 1993 Jun;147(6):653-7 [8506834.001]
  • [Cites] Science. 1992 Aug 28;257(5074):1248-51 [1325670.001]
  • [Cites] N Engl J Med. 1990 Dec 27;323(26):1806-13 [2247119.001]
  • [Cites] Horm Res. 1987;25(1):5-12 [3817758.001]
  • [Cites] Am J Dis Child. 1988 Oct;142(10):1061-4 [3140654.001]
  • [Cites] Can J Comp Med. 1978 Oct;42(4):466-72 [217508.001]
  • [Cites] Am J Pathol. 1974 May;75(2):363-74 [4362916.001]
  • [Cites] Pediatr Nephrol. 2000 Oct;14(12):1083-7 [11045391.001]
  • [Cites] Pediatr Nephrol. 2000 Dec;15(3-4):302-16 [11149130.001]
  • [Cites] J Endocrinol. 2000 Feb;164(2):225-38 [10657858.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1362-8 [11070100.001]
  • [Cites] Gene Ther. 1999 Nov;6(11):1898-903 [10602386.001]
  • [Cites] Endocr Relat Cancer. 1999 Jun;6(2):303-6 [10731123.001]
  • [Cites] Endocrinol Metab Clin North Am. 2009 Sep;38(3):613-24 [19717007.001]
  • [Cites] Expert Opin Emerg Drugs. 2009 Sep;14(3):455-70 [19650748.001]
  • [Cites] Ann Pharmacother. 2009 Jul;43(7):1338-46 [19584394.001]
  • [Cites] BJU Int. 2009 Nov;104(9):1191-7 [19624596.001]
  • [Cites] Eur J Endocrinol. 2009 Jul;161(1):119-30 [19383806.001]
  • [Cites] Endocr Rev. 2009 May;30(3):241-63 [19403887.001]
  • [Cites] J Vet Med Sci. 2009 Apr;71(4):431-9 [19420845.001]
  • [Cites] Curr Opin Urol. 2009 May;19(3):315-21 [19342958.001]
  • [Cites] Singapore Med J. 2009 Feb;50(2):e68-70 [19296015.001]
  • [Cites] Horm Res. 2009 Jan;71 Suppl 1:57-63 [19153508.001]
  • [Cites] Ann Endocrinol (Paris). 2008 Sep;69 Suppl 1:S44-52 [18954859.001]
  • [Cites] Curr Drug Targets. 2003 Oct;4(7):586-97 [14535656.001]
  • [Cites] Horm Res. 2003;60(Suppl 1):60-7 [12955020.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):2993-8 [12843131.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7484-9 [12032309.001]
  • [Cites] Eur J Endocrinol. 2002 Mar;146(3):339-46 [11888840.001]
  • [Cites] Ann Intern Med. 2002 Feb 19;136(4):320-34 [11848730.001]
  • [Cites] Lancet. 2001 Jun 2;357(9270):1743-8 [11403810.001]
  • [Cites] Bone. 2001 Apr;28(4):410-3 [11336922.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1511-7 [11297576.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1347-52 [11038205.001]
  • [Cites] Eur J Endocrinol. 2000 Nov;143(5):667-71 [11078991.001]
  • (PMID = 20652035.001).
  • [ISSN] 1687-9856
  • [Journal-full-title] International journal of pediatric endocrinology
  • [ISO-abbreviation] Int J Pediatr Endocrinol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2905899
  •  go-up   go-down


5. Porpiglia F, Fiori C, Daffara F, Zaggia B, Bollito E, Volante M, Berruti A, Terzolo M: Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol; 2010 May;57(5):873-8
University of Turin Instituional Repository AperTO. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer.
  • BACKGROUND: Although there is consensus that laparoscopy is the standard of care for the resection of benign adrenal tumours, there is controversy regarding the role of laparoscopy for the resection of adrenocortical cancer (ACC).
  • OBJECTIVE: The aim of the present study was to review the ACC database of the San Luigi Hospital to compare the oncologic effectiveness of open adrenalectomy (OA) versus laparoscopic adrenalectomy (LA) in the treatment of patients with stage I and II ACC.
  • DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective analysis involving 43 patients with stage I and II ACC who had undergone radical surgery.
  • CONCLUSIONS: The present findings provide interesting evidence that OA and LA may be comparable in terms of recurrence-free survival for patients with stage I and II ACC when the principles of surgical oncology are respected.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20137850.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Krsek M: [Adrenal cancer]. Vnitr Lek; 2009 Jan;55(1):54-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenal cancer].
  • Adrenal cancer is a rare disease which is often diagnosed at a late stage and usually has a poor prognosis.
  • Further, clinical presentation, diagnostic approach and current treatment options in patients with adrenal cancer are summarized.
  • The multidisciplinary approach as well as centralized care is necessary for successful management of patients with adrenal cancer and for improvement of their poor prognosis.
  • [MeSH-major] Adrenal Cortex Neoplasms

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vnitr Lek. 2009 Jan;55(1):6 [19227948.001]
  • (PMID = 19227956.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 62
  •  go-up   go-down


7. Ambika S, Melton A, Lee D, Hesketh PJ: Massive retroperitoneal adrenal hemorrhage secondary to lung cancer metastasis treated by adrenal artery embolization. Clin Lung Cancer; 2009 Sep;10(5):E1-4
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive retroperitoneal adrenal hemorrhage secondary to lung cancer metastasis treated by adrenal artery embolization.
  • The development of adrenal hemorrhage from lung cancer metastasis is extremely rare.
  • A 54-year-old woman with stage IV non-small-cell lung cancer and known bilateral adrenal metastasis developed severe right-sided abdominal pain while undergoing chemotherapy treatment.
  • The bleeding vessel was identified as the right middle adrenal artery.
  • The patient underwent successful transcatheter embolization (TCE) and occlusion of the right middle adrenal artery using metallic coils, with resolution of the abdominal pain and stabilization of her hemoglobin.
  • TCE can be used to control hemorrhage arising from metastatic involvement of the adrenal gland.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Catheterization, Peripheral. Embolization, Therapeutic. Hemorrhage / chemically induced. Hemorrhage / therapy. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology
  • [MeSH-minor] Adrenal Glands / blood supply. Adrenal Glands / pathology. Carboplatin / administration & dosage. Carboplatin / adverse effects. Diagnostic Imaging. Female. Flank Pain. Glutamates / administration & dosage. Glutamates / adverse effects. Guanine / administration & dosage. Guanine / adverse effects. Guanine / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Staging. Pemetrexed. Retroperitoneal Space / pathology


8. Fenske W, Völker HU, Adam P, Hahner S, Johanssen S, Wortmann S, Schmidt M, Morcos M, Müller-Hermelink HK, Allolio B, Fassnacht M: Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer; 2009 Sep;16(3):919-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma.
  • Owing to the rarity of adrenocortical carcinoma (ACC) no prognostic markers have been established beyond stage and resection status.
  • Accelerated glycolysis is a characteristic feature of cancer cells and in a variety of tumour entities key factors in glucose metabolism like glucose transporter 1 and 3 (GLUT1 and -3), transketolase like-1 enzyme (TKTL1) and pyruvate kinase type M2 (M2-PK) are overexpressed and of prognostic value.
  • Immunohistochemical analysis was performed on tissue microarrays of paraffin-embedded tissue samples from 167 ACCs, 15 adrenal adenomas and 4 normal adrenal glands.
  • In conclusion, GLUT1 is a highly promising stage-independent, prognostic marker in ACC.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / metabolism. Glucose Transporter Type 1 / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Biomarkers, Tumor / physiology. Female. Glucose / metabolism. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465749.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human; IY9XDZ35W2 / Glucose
  •  go-up   go-down


9. Pagès PM, Dufour C, Fasola S, Michon J, Boutard P, Gentet JC, Hartmann O: Bilateral adrenal neuroblastoma. Pediatr Blood Cancer; 2009 Feb;52(2):196-202
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral adrenal neuroblastoma.
  • BACKGROUND: Bilateral adrenal neuroblastoma is extremely rare.
  • PROCEDURES: We retrospectively identified and reviewed 15 cases of bilateral adrenal neuroblastoma, treated between 1988 and 2004, by the French Society of Pediatric Oncology.
  • RESULTS: Median age at diagnosis was 4 months in our cohort whereas it was 3 months in the literature.
  • Ten out of 15 patients in our cohort and 18/39 cases in the literature were classified as stage 4S according to the International Neuroblastoma Staging System (INSS).
  • The incidence of stage 4S was significantly higher than that described in other neuroblastoma cohorts (P = 10(-4)).
  • Five-year overall survival was 90% for stage 4S.
  • However, the low incidence of relapse and the risk of adrenal failure if radical surgery is performed, argue against an aggressive surgical approach.
  • [MeSH-major] Adrenal Gland Neoplasms / epidemiology. Neuroblastoma / epidemiology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18951434.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins
  •  go-up   go-down


10. Ng VW, Ma RC, So WY, Choi KC, Kong AP, Cockram CS, Chow CC: Evaluation of functional and malignant adrenal incidentalomas. Arch Intern Med; 2010 Dec 13;170(22):2017-20
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of functional and malignant adrenal incidentalomas.
  • BACKGROUND: Adrenal incidentalomas are adrenal masses discovered inadvertently.
  • We undertook this study to review the clinical characteristics of patients with adrenal incidentalomas who presented to a tertiary endocrine center in Hong Kong.
  • METHODS: Retrospective review of all 139 cases of adrenal incidentalomas that were referred to the Endocrine Centre of the Prince of Wales Hospital between June 1, 2000, and May 31, 2007.
  • We reviewed detailed patient history, physical examination findings, and symptoms and signs related to hormonal hypersecretion or malignant neoplasm and recorded clinical indications for performing diagnostic radiological imaging.
  • RESULTS: Sixty-one patients (43.9%) had nonfunctional benign adrenal adenomas, 52 (37.4%) had functional lesions, 15 (10.8%) had malignant adrenal lesions, and the remaining 11 (7.9%) had varying adrenal disease.
  • Only 5 of the 27 patients with cortisol-secreting adrenal incidentalomas had symptoms or signs of excess cortisol levels at presentation.
  • CONCLUSIONS: Adrenal incidentaloma is a commonly encountered clinical problem.
  • Functional or primary malignant adrenal incidentalomas can be detected at an earlier stage during hormonal and radiological evaluations, which provides an opportunity for further management.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenocortical Adenoma / diagnosis. Aldosterone / secretion. Catecholamines / secretion. Hydrocortisone / secretion
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Corticotropin-Releasing Hormone / blood. Early Detection of Cancer. Female. Hong Kong / epidemiology. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21149760.001).
  • [ISSN] 1538-3679
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Catecholamines; 4964P6T9RB / Aldosterone; 9015-71-8 / Corticotropin-Releasing Hormone; WI4X0X7BPJ / Hydrocortisone; Adrenal incidentaloma
  •  go-up   go-down


11. Horstmann M, Merseburger AS, Stenzl A, Kuczyk M: [Systemic therapy of malignant adrenal tumors]. Urologe A; 2006 May;45(5):605-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Systemic therapy of malignant adrenal tumors].
  • Systemic treatment of advanced-stage adrenal malignancies is most often only palliative.
  • Mitotane alone or in combination with other chemotherapeutic agents such as cisplatin, etoposide, and vincristine are established therapeutic concepts for the treatment of metastatic adrenal cancer.
  • New therapeutic options are tumor vaccination and treatment with antiangiogenic drugs.
  • Metaiodobenzylguanidine as a radiotherapeutic drug or chemotherapeutic combination therapies that include cyclophosphamide, vincristine, and dacarbazine are applied for systemic treatment of malignant pheochromocytomas.. However, the clinical efficacy of the latter regimen needs further evaluation.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / methods. Neoplasm Recurrence, Local / prevention & control. Palliative Care / methods. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1990 Aug;71(2):497-504 [2380344.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1533-5 [8111724.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):657-66 [16172198.001]
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1195-201 [2325710.001]
  • [Cites] Eur J Surg Oncol. 2003 Apr;29(3):278-83 [12657240.001]
  • [Cites] J Endocrinol Invest. 1997 Dec;20(11):648-58 [9492103.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):667-80 [16172199.001]
  • [Cites] Cancer. 2002 May 1;94(9):2333-43 [12015757.001]
  • [Cites] J Nucl Biol Med. 1991 Oct-Dec;35(4):269-76 [1823834.001]
  • [Cites] Tumori. 1992 Oct 31;78(5):345-8 [1494808.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):161-5 [8418229.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] J Clin Oncol. 1989 Apr;7(4):499-508 [2926472.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1398-403 [2949824.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1281-7 [11106117.001]
  • [Cites] JAMA. 1973 Mar 5;223(10):1109-12 [4739370.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1159-65 [10699907.001]
  • [Cites] Am J Clin Oncol. 1999 Aug;22(4):364-70 [10440191.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3145-55 [8242539.001]
  • [Cites] Curr Probl Cancer. 1985 May;9(5):1-89 [3021396.001]
  • [Cites] Pharmacol Res. 2002 Dec;46(6):551-5 [12457630.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2001 Jul;92(5):593-6 [11517573.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(5):361-6 [11716230.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Sep;41(3):299-307 [7955436.001]
  • [Cites] Endocr Rev. 2003 Oct;24(5):600-32 [14570746.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1317-24 [9141510.001]
  • [Cites] Hypertension. 1985 Jan-Feb;7(1):118-24 [3980054.001]
  • [Cites] Surgery. 1997 Dec;122(6):1212-8 [9426440.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:54-60 [12381541.001]
  • [Cites] Ann Intern Med. 1988 Aug 15;109(4):267-73 [3395037.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Apr;76(4):1019-24 [8473376.001]
  • (PMID = 16622644.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 31
  •  go-up   go-down


12. Paton BL, Novitsky YW, Zerey M, Harrell AG, Norton HJ, Asbun H, Kercher KW, Heniford BT: Outcomes of adrenal cortical carcinoma in the United States. Surgery; 2006 Dec;140(6):914-20; discussion 919-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of adrenal cortical carcinoma in the United States.
  • BACKGROUND: Improvements in the sensitivity of radiographic imaging have lead to an increase in the number of adrenal masses diagnosed.
  • The purpose of this study is to determine if technologic advancements have resulted in the diagnosis of earlier-staged adrenal cortical cancer (ACC) and to determine if the survival of patients with ACC has improved over the past 15 years.
  • Changes in demographics, stage, size, and treatment were analyzed by standard statistical testing.
  • RESULTS: We identified 602 patients with a mean age of 53 years and an average tumor size of 11.8 cm.
  • Age (P = .10), tumor size (P = .85), tumor stage (P = .45), and 5-year survival (P = .5) did not change over the 15-year study.
  • CONCLUSIONS: Over the 15-year study, patients with ACC were not diagnosed at an earlier stage or with tumors smaller, and survival did not improve.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / pathology. Neoplasm Staging. SEER Program / statistics & numerical data
  • [MeSH-minor] Adrenal Glands / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17188138.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Iwanami T, Uramoto H, Baba T, Takenaka M, Yokoyama E, Oka S, So T, Ono K, So T, Takenoyama M, Hanagiri T, Iwata T, Inoue M, Yasumoto K: [Treatment recommendations for adrenal metastasis of non-small cell lung cancer]. Kyobu Geka; 2010 Dec;63(13):1101-6; discussion 1106-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment recommendations for adrenal metastasis of non-small cell lung cancer].
  • To evaluate the optimum treatment strategy for metastatic adrenal tumors derived from non-small cell lung cancer (NSCLC), we retrospectively analyzed 17 consecutive cases (8 resection cases: 4 synchronous and 4 metachronous: 9 non-resection cases: 3 synchronous and 6 metachronous) who received surgical resection for NSCLC.
  • The mean interval after lung resection and treatment of metachronous adrenal metastasis was 9.9 months.
  • The mean time to progression from treatment of metachronous adrenal metastasis to disease progression was 8.9 months.
  • A survival analysis showed no significant prognostic difference between the patient age, gender, pathological stage, synchronous/metachronous classification, CEA, and site of metastases.
  • The 2-year survival of patients following resection versus those who did not undergo a resection for adrenal metastasis was 62.5 and 22.8%, respectively.
  • These data indicate that metastatic adrenal tumors should be resected if the patient can tolerate surgery after appropriate selection.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


14. Pineda C, Cadogan KV, Cadogan MA: Distribution of metastases in NSCLC: Economic impact of imaging. J Clin Oncol; 2009 May 20;27(15_suppl):e19036

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • " METHODS: We retrospectively reviewed the CT data of 184 patients with Stage 4 NSCLC.
  • This compares with 42 patients with adrenal metastases, 81 with liver metastases, 80 with bone metastases, 112 with hilar adenopathy, and 159 with mediastinal adenopathy. (See Table ) Conclusions: The cost of a CT of the pelvis varies, but is estimated at approximately $2000[Fred, Herbert L., MD, MACP.
  • SEER Cancer Statistics Review, 1975-2005.
  • National Cancer Institute. 03JAN2009. http://seer.cancer.gov/csr/1975_2005/ .].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Zhang W, Dahlberg SE, Yang D, Sandler AB, Brahmer JR, Schiller JH, Carbone DP, Johnson DH, Lenz H: Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599. J Clin Oncol; 2009 May 20;27(15_suppl):8032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have shown certain germline polymorphisms (SNPs) are associated with clinical outcome in advanced breast cancer pts treated with paclitaxel plus bev and in advanced colorectal cancer pts treated with first line 5-FU or capecitabine in combination with oxaliplatin and bev.
  • Multivariable Cox models adjusted for gender, PS, stage, adrenal, liver and bone mets were separately fitted for each SNP to obtain estimates of hazard ratios.
  • Pts with mutant homozygote CC genotype for ICAM1 T469C had significantly higher tumor response rate (39%) than heterozygote CT (13%) and homozygote TT (20%) genotype (Fisher's test, p=0.04).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962832.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Miyazaki T, Tagawa T, Nakamura A, Yamasaki N, Hashizume S, Matsumoto K, Taguchi T, Morino S, Nagayasu T: [Surgical treatment for stage IV lung cancer]. Kyobu Geka; 2006 Jan;59(1):36-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for stage IV lung cancer].
  • OBJECTIVE: To find out the optimal surgical indication in stage IV lung cancer patients, we evaluated them retrospectively.
  • The metastatic lesions were lung (33.9%), brain (24.2%), liver, bone, adrenal gland and so on.
  • The overall survival rate of stage IV lung cancer was 10.4% at 5-year.
  • Two were lung and the others were brain and adrenal gland metastasis without lymph node metastasis.
  • CONCLUSION: Stage IV lung cancer with lung or brain or adrenal gland metastasis without lymph node metastasis should be resected.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging / mortality. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440683.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Margery J, Milleron B, Vaylet F, Grahek D, Lebeau B, Mangiapan G, Bonardel G, de Labriolle-Vaylet C, Meignan M, Carette MF, Talbot JN, Housset B: [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study]. Rev Pneumol Clin; 2010 Oct;66(5):313-20
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
  • [Transliterated title] Impact de la tomographie par émission de positons au 18-FDG dans la prise en charge des patients porteurs d'un cancer bronchique non à petites cellules a priori opérable. Etude prospective multicentrique française.
  • BACKGROUND: Whole-body (18)F-deoxyglucose positron emission tomography (FDG-PET) has the potential to improve the management of non-small-cell lung cancer (NSCLC).
  • The stage was lowered in eight cases (9%) and raised in 18 cases (20.2%).
  • These modifications were retrospectively justified in 9/19 cases, and consisted of 2/4 modifications of the surgical procedure (one hilar and one adrenal metastasis not confirmed histologically), 4/12 further investigations (axillary and liver biopsies, mediastinoscopy, occult colon cancer) and three indications for palliative treatment, in patients who all died within 3 months after FDG-PET.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonic Neoplasms / radionuclide imaging. Decision Making. False Positive Reactions. Female. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis / radionuclide imaging. Male. Mediastinoscopy. Middle Aged. Neoplasm Staging. Neoplasms, Unknown Primary / radionuclide imaging. Palliative Care. Patient Care Planning. Pneumonectomy. Prospective Studies. Retrospective Studies. Tomography, X-Ray Computed. Whole Body Imaging

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21087727.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Cho MM, Kobayashi K, Aoki T, Nishioka K, Yoshida K, Hatano N, Hirose H, Moon JH, Matsumoto T, Uemura Y, Kaneko T, Okagawa K: Surgical resection of solitary adrenal metastasis from esophageal carcinoma following esophagectomy. Dis Esophagus; 2007;20(1):79-81
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of solitary adrenal metastasis from esophageal carcinoma following esophagectomy.
  • However, we experienced a case with good prognosis following resection of a solitary adrenal metastatic tumor.
  • The patient was a 70-year-old man diagnosed with type 2 esophageal cancer (Lt-Ae, T2N1M0, Stage IIB) who was treated with esophagectomy.
  • Eight months following surgery, solitary adrenal metastasis was detected by CT, and was resected.
  • To the best of our knowledge, only five cases with resected solitary adrenal metastases including our case, have been reported, and show a greater than 1-year survival.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227316.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Gonzalez RJ, Tamm EP, Ng C, Phan AT, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE: Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery; 2007 Dec;142(6):867-75; discussion 867-75
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
  • BACKGROUND: Adrenal cortical carcinoma (ACC) is a rare disease in which recurrence after surgery is common.
  • Higher stage at presentation (P = .002) and tumor cortisol production (P = .007) were associated with a worse OS.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / surgery. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063070.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


20. Ito K, Nakazawa H, Marumo K, Ozono S, Igarashi T, Shinohara N, Fukuda M, Tsushima T, Naito S, Hayakawa M, Japanese Society of Renal Cancer: Risk factors for ipsilateral adrenal involvement in renal cell carcinoma. Urology; 2008 Aug;72(2):354-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for ipsilateral adrenal involvement in renal cell carcinoma.
  • OBJECTIVES: We retrospectively review patients treated for renal cell carcinoma at 19 institutes in collaboration with the Japanese Society of Renal Cancer, to clarify the risk factors for ipsilateral adrenal involvement (IADI).
  • RESULTS: Preoperative computed tomography (CT) could detect 83.3% of the instances of synchronous ipsilateral adrenal metastasis.
  • Patients with IADI had significantly larger primary tumors, higher pT stages and histologic grades, and higher percentages of upper pole involvement, microvascular invasion, spindle-cell-type tumors, lymph node metastasis (LNM), and distant metastasis (DM) outside the ipsilateral adrenal gland (IAd) than in control patients.
  • Multivariate logistic regression analysis of clinical factors revealed that tumor size greater than 5.5 cm, pT stage of 3 or higher, LNM, and DM outside IAd, but not upper pole involvement, were significant predictors of IADI.
  • CONCLUSIONS: Tumor size greater than 5.5 cm, clinical T stage of 3 or higher (tumor for which pT stage of 3 or higher is suspected), LNM, and DM outside IAd seemed to be important preoperative indicators of IADI.
  • Moreover, patients with renal cell carcinoma who have normal adrenal on CT, have a T1 tumor extending less than 5.5 cm, and have neither LNM nor DM are good candidates for adrenal-sparing nephrectomy.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18468657.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Investigator] Miyao N; Senga Y; Miyajima A; Oya M; Murai M; Tomomasa H; Maruyama O; Horie S; Saika T; Fujimoto K; Hirao Y; Kobayashi M; Takayama T; Shima M; Terachi T; Nagamori S; Nakamoto T; Hisaya T; Kanayama H; Eto M; Mizuguchi Y
  •  go-up   go-down


21. Lutterbach J, Pagenstecher A, Weyerbrock A, Schultze-Seemann W, Waller CF: Early-stage penile carcinoma metastasizing to brain: case report and literature review. Urology; 2005 Aug;66(2):432
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage penile carcinoma metastasizing to brain: case report and literature review.
  • Early-stage penile squamous cell carcinoma with subsequent distant metastases is rare.
  • We report a case of a 35-year-old man with Stage pT1pN0 penile squamous cell carcinoma who underwent circumcision and bilateral inguinal lymphadenectomy.
  • Further in the disease course, the patient developed metastases in the kidney, adrenal gland, retroperitoneal lymph nodes, lung, and brain.
  • Forty months after the first diagnosis, the patient died of thromboembolic complications.
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098372.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


22. Kim HM, Ikeda M, Okano M, Miyoshi N, Hirose H, Yamashita S, Takemasa I, Mizushima T, Yamamoto H, Sekimoto M, Doki Y, Mori M: [A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2548-50
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy].
  • We report a case of 57-year-old woman suffering from advanced sigmoid colon cancer with adrenal and para-aortic lymph node recurrence.
  • Sigmoidectomy was performed for sigmoid colon cancer in January 2002.
  • Pathological staging was Stage II (pT3, pN0, pM0, Cur A).
  • However, adrenal and para-aortic lymph node recurrence was detected in February 2007, and mFOLFOX6 was performed as preoperative chemotherapy.
  • She had no recurrence for almost 3 years after a resection of adrenal and para-aortic lymph node metastasis.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lymphatic Metastasis. Sigmoid Neoplasms / pathology. Sigmoid Neoplasms / therapy
  • [MeSH-minor] Adrenalectomy. Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Female. Fluorouracil / therapeutic use. Hepatectomy. Humans. Leucovorin / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Organoplatinum Compounds / therapeutic use. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224635.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 1548R74NSZ / Tegafur; 2S9ZZM9Q9V / Bevacizumab; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; 1-UFT protocol; Folfox protocol
  •  go-up   go-down


23. Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, Morris D, American College of Chest Physicians: Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest; 2007 Sep;132(3 Suppl):277S-289S
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition).
  • BACKGROUND: Stage IV non-small cell lung cancer (NSCLC) remains a treatable but incurable disease.
  • The one exception is the addition of bevacizumab, an antiangiogenic agent, to carboplatin/paclitaxel in patients with stage IV disease and good PS.
  • In patients with stage IV NSCLC and PS of 2, chemotherapy is recommended, but the optimal approach has not been defined.
  • Because stage IV NSCLC is incurable, quality-of-life issues are important, and tools exist to monitor a patient's quality of life during therapy.
  • Last, patients need to be informed of the implication of the diagnosis of stage IV NSCLC and be educated about treatment options that are available to them.
  • CONCLUSIONS: Advances have been made in stage IV NSCLC, and the appropriate use of chemotherapy continues to evolve on the basis of well-designed clinical trials that address critical issues in this population.
  • [MeSH-major] Adrenal Gland Neoplasms / therapy. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy. Pancoast Syndrome / therapy
  • [MeSH-minor] Combined Modality Therapy. Disease-Free Survival. Evidence-Based Medicine. Humans. Neoplasm Staging


24. Britvin TA, Kazantseva IA, Kalinin AP, Kushlinskii NE: Vascular endothelium growth factor in the sera of patients with adrenal tumors. Bull Exp Biol Med; 2005 Aug;140(2):228-30
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelium growth factor in the sera of patients with adrenal tumors.
  • Serum levels of vascular endothelium growth factor were measured in 43 patients with adrenal tumors and 25 healthy subjects.
  • The mean blood levels of the factor in patients with adrenal tumors significantly surpassed the control.
  • The levels of this factor were maximum in patients with adrenocortical cancer, but its mean level differed negligibly from that in other morphological variants of tumors.
  • The level of vascular endothelium growth factor tended to increase with increasing the stage of adrenocortical cancer.
  • A direct correlation was revealed between the level of vascular endothelium growth factor and tumor size in adrenocortical cancer and aldosterone-producing adenoma.
  • Presumably, vascular endothelium growth factor is involved into mechanisms of growth, invasion, and metastatic growth of adrenocortical cancer.
  • [MeSH-major] Adrenal Gland Neoplasms / blood. Gene Expression Regulation, Neoplastic. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16283008.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


25. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, Shariat SF, Guazzoni G, Montorsi F, Karakiewicz PI: The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer; 2010 Mar;46(4):713-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation.
  • BACKGROUND: A reclassification of the International Union Against Cancer (UICC) staging system for adrenocortical carcinoma (ACC) patients has recently been proposed by the European Network for the Study of Adrenal Tumors (ENSAT) to better discriminate between cancer-specific mortality (CSM) risk strata.
  • Conversely, a statistically significant difference was observed between 2008 ENSAT stage II and stage III patients (p<0.001).
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Neoplasm Staging / standards

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20044246.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


26. Bisenkov LN, Shalaev SA, Orzheshkovskiĭ OV, Platunov SK, Efremov FA: [One-stage operations on the lungs and other organs in multifocal and metastatic cancer]. Khirurgiia (Mosk); 2005;(4):33-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [One-stage operations on the lungs and other organs in multifocal and metastatic cancer].
  • Surgical treatment of 135 patients with multifocal and metastatic cancer of the lungs and other organs is analyzed.
  • Surgical procedures were performed in 109 patients, 37 (33.9%) of them were one-stage.
  • One-stage procedures meet the requirements of radical surgery and are most preferable biologically and clinically.
  • As cytoreductive operations, one-stage resections improve the condition of the patients, enable effective polychemotherapy.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Digestive System Neoplasms / surgery. Kidney Neoplasms / surgery. Lung Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Neoplasms, Second Primary / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Colonic Neoplasms / diagnosis. Colonic Neoplasms / surgery. Diagnosis, Differential. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / surgery. Esophagoplasty. Gastrectomy. Humans. Length of Stay. Nephrectomy. Pneumonectomy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / surgery. Time Factors


27. Siemer S, Lehmann J, Loch A, Becker F, Stein U, Schneider G, Ziegler M, Stöckle M: Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol; 2005 Jan;173(1):33-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current TNM classification of renal cell carcinoma evaluated: revising stage T3a.
  • PURPOSE: : Recent studies of rare cases of pT3a renal cell carcinoma extending directly into the adrenal gland showed worse survival than in other pT3a cases and recategorization as stage pT4 was suggested.
  • We assessed the prognostic validity of a stage pT3a diagnosis based on perirenal fat infiltration.
  • Focusing on pT3a tumors, as defined by perirenal fat infiltration, numerous clinical and histopathological parameters were investigated by univariate and multivariate statistical methods with cancer specific survival as the primary end point.
  • In patients with pT3a tumors tumor size was a significant parameter predicting survival.
  • The most significant cutoff value for tumor size in pT3a disease was 7 cm.
  • Therefore, to assess the prognostic value of the current T classification in regard to T3a tumors we excluded patients with tumor stage cM+ for further subgroup analysis.
  • After splitting pT3a into a modified T1/T2 classification a significant difference in 5-year survival analysis for a modified T1/T2 stage was found (pT1 plus pT3a less than 7 cm 90% vs pT2 plus pT3a greater than 7 cm 73%, p <0.001).
  • Subsequently multivariate analysis in all 1,794 patients showed that modified T stage was an independent significant predictor of cancer specific survival.
  • Tumors directly infiltrating the adrenal gland should be reclassified as T4.
  • [MeSH-minor] Humans. Neoplasm Invasiveness. Neoplasm Staging. Nephrectomy. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592020.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Caruso DA, Orme LM, Amor GM, Neale AM, Radcliff FJ, Downie P, Tang ML, Ashley DM: Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer; 2005 Mar 15;103(6):1280-91
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma.
  • BACKGROUND: A Phase I study of 11 pediatric patients with newly diagnosed, Stage 4 neuroblastoma was conducted using monocyte-derived dendritic cells (DC) pulsed with tumor RNA to produce antitumor vaccines (DC(RNA)).
  • Despite this, two of three patients tested showed a tumor-specific humoral immune response to DC(RNA).
  • Among the patients who had measurable disease at the time of DC(RNA) vaccine, none showed any objective tumor response.
  • CONCLUSIONS: DC(RNA) vaccines were both safe and feasible in children with Stage 4 neuroblastoma.
  • Humoral responses to tumor were detected, although remained immunosuppressed at the time of administration, limiting efficacy.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Cancer Vaccines / therapeutic use. Dendritic Cells / immunology. Neuroblastoma / pathology. Neuroblastoma / therapy. RNA, Neoplasm / immunology
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Immunotherapy / methods. Leukapheresis / methods. Male. Neoplasm Staging. Probability. Retroperitoneal Neoplasms / immunology. Retroperitoneal Neoplasms / mortality. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / therapy. Risk Assessment. Sensitivity and Specificity. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693021.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / RNA, Neoplasm
  •  go-up   go-down


29. Ishido K, Koizumi W, Tanabe S, Higuchi K, Sasaki T, Katada C, Azuma M, Saigenji K, Futawatari N, Saegusa M: A patient with stage IV type 4 advanced gastric cancer who had a complete pathological response to short-term treatment with S-1 alone. Anticancer Drugs; 2008 Oct;19(9):921-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with stage IV type 4 advanced gastric cancer who had a complete pathological response to short-term treatment with S-1 alone.
  • Stage IV (cT3, cN3, cH0, cM1) type 4 advanced gastric cancer was diagnosed.
  • The left adrenal gland and the paragastric, mediastinal, and abdominal para-aortic lymph nodes were enlarged.
  • The tumor had shrunk and was severely deformed.
  • Abdominal computed tomography revealed that ascites and enlargement of the left adrenal gland and paragastric lymph nodes had resolved.
  • The primary gastric tumor, resected lymph nodes, and a peritoneal-lavage specimen were all negative for tumor.
  • Histologically, the tumor had a complete pathological response to S-1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18766007.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


30. Schindler T, Yu C, Rossleigh M, Pereira J, Cohn R: False-positive MIBG uptake in pneumonia in a patient with stage IV neuroblastoma. Clin Nucl Med; 2010 Sep;35(9):743-5
MedlinePlus Health Information. consumer health - Pneumonia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-positive MIBG uptake in pneumonia in a patient with stage IV neuroblastoma.
  • A 32-month-old female child with a history of stage IV favorable biology neuroblastoma with a 123-I MIBG (metaiodobenzylguanidine scan) avid adrenal mass, with retroperitoneal nodal extension and bony metastasis, was in complete remission after intense multimodal therapy.
  • Seventeen months after diagnosis a surveillance 123-I MIBG scan showed abnormal tracer uptake in the midzone of the right thorax.
  • [MeSH-minor] Child, Preschool. False Positive Reactions. Female. Follow-Up Studies. Humans. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20706060.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


31. Butler C, Butler WM, Rizvi AA: Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr Pract; 2010 May-Jun;16(3):441-5
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma.
  • An 8-cm left adrenal lesion was found on computed tomography, removed surgically, and confirmed as adrenal carcinoma on pathologic examination.
  • Postoperative scanning revealed metastases to both lungs and the liver that were confirmed by fine-needle biopsy, thus establishing stage IV disease.
  • CONCLUSION: Multiple kinase inhibitors such as sorafenib provide targeted oncologic treatment and may be effective in treating advanced adrenal cancer.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061282.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


32. Kim EY, Yoo SY, Kim JH, Sung KW: Pancreatic metastasis in a child suffering with treated stage 4 neuroblastoma. Korean J Radiol; 2008 Jan-Feb;9(1):84-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis in a child suffering with treated stage 4 neuroblastoma.
  • We present here a very rare case of metastatic relapse in the pancreas of a 4-year-old boy who had been treated for stage 4 neuroblastoma.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Neuroblastoma / secondary. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Child, Preschool. Contrast Media. Diagnosis, Differential. Diagnostic Imaging. Humans. Male


33. Casey EM, Harb W, Bradford D, Bufill J, Nattam S, Patel J, Fisher W, Latz JE, Li X, Wu J, Hanna N: Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. J Thorac Oncol; 2010 Nov;5(11):1815-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
  • INTRODUCTION: : Bevacizumab is approved in combination with chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC).
  • METHODS: : ELIGIBILITY CRITERIA: ≥18 years of age, chemonaïve, stage IIIB/IV nonsquamous NSCLC, and Eastern Cooperative Oncology Group performance status 0 to 1.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adrenal Gland Neoplasms / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carboplatin / administration & dosage. Double-Blind Method. Female. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Indoles / administration & dosage. Male. Middle Aged. Neoplasm Staging. Pemetrexed. Placebos. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881647.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Glutamates; 0 / Indoles; 0 / Placebos; 04Q9AIZ7NO / Pemetrexed; 2S9ZZM9Q9V / Bevacizumab; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin; UC96G28EQF / enzastaurin
  •  go-up   go-down


34. Yasumoto T, Hayashi S, Shimizu J, Dono K, Nakata S, Sato M, Kitada M, Shimano T: [Radiofrequency ablation combined with transcatheter arterial chemoembolization for the local recurrent tumor after resection of the adrenal metastasis from hepatocellular carcinoma--a case report]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2371-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiofrequency ablation combined with transcatheter arterial chemoembolization for the local recurrent tumor after resection of the adrenal metastasis from hepatocellular carcinoma--a case report].
  • We report a case of local recurrent tumor after a resection of right adrenal metastasis from hepatocellular carcinoma successfully treated with radiofrequency ablation combined with transcatheter arterial chemoembolization.
  • The lesions were judged to be T4, N0, M0 and Stage IV,then, he was treated as an outpatient on a regular schedule.
  • In July 2003, a right adrenal tumor 2 cm in diameter was detected by computed tomography (CT), but the value of the adrenocortical hormones were normal on blood examination, and he was observed at regular intervals.
  • In February 2005, the adrenal lesion enlarged to 5 cm in diameter and the value of PIVKA-II became high on blood examination, so April 2005, a surgical resection was performed, and it was diagnosed as the metastasis from HCC.
  • In July 2008, the recurrent tumor 3 cm in diameter was observed in the right retroperitoneum.
  • It was considered inoperable because of the past operation, and transcatheter arterial chemoembolization of an inferior adrenal artery and a fine branch through a right sub-phrenic artery was performed for the recurrent tumor, and one week after the embolization, radiofrequency ablation was treated by CT fluoroscopy guidance.
  • Ten months after the tumor embolization combined with radiofrequency ablation, there were no local and distant recurrences observed by CT examination.
  • Transcatheter arterial embolization combined with radiofrequency ablation is considered as a feasible and effective method for not only HCC but also for a local recurrent tumor after resection of the adrenal metastasis from hepatocellular carcinoma.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Carcinoma, Hepatocellular / therapy. Catheter Ablation. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037426.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Matsuoka T, Morikage N, Kuga T, Nakayama T, Fujii Y: [Metastatic carcinoma of the adrenal gland from large cell neuroendocrine carcinoma; report of a case]. Kyobu Geka; 2005 Jun;58(6):499-503
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic carcinoma of the adrenal gland from large cell neuroendocrine carcinoma; report of a case].
  • A 69-year-old man had undertaken left upper lobectomy (ND 2 a) with partial resection of the left lower lobe under the diagnosis of a primary lung cancer, T2N0M0, stage IB in June, 2002.
  • The histopathological diagnosis was large cell neuroendocrine carcinoma (LCNEC), T3N0M0, stage IIB.
  • Abdominal computed tomography (CT) revealed an enhanced tumor in the left adrenal lesion, 3 cm in diameter, in October, 2003.
  • Tumor marker, NSE was slightly elevated on blood examination.
  • Histopathologically, the tumor was diagnosed as metastasis of LCNEC.
  • Although a prognosis of LCNEC is poor in general, we should consider the resection of metastatic carcinoma of the adrenal gland from LCNEC for long-term survival expectantly.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / secondary. Carcinoma, Neuroendocrine / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15957427.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Ramírez Plaza CP, Santoyo Santoyo J, Domínguez López ME, Eloy-García Carrasco C, Cobo Dols M, Suárez Muñoz MA, Fernández Aguilar JL, de la Fuente Perucho A: [Adrenal carcinoma: 7 year disease free survival after complete primary tumor resection and repeated resection of local-regional and distant recurrences. Review after one case with poor initial life expectancy]. Arch Esp Urol; 2005 Mar;58(2):115-9
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenal carcinoma: 7 year disease free survival after complete primary tumor resection and repeated resection of local-regional and distant recurrences. Review after one case with poor initial life expectancy].
  • [Transliterated title] Carcinoma suprarrenal: supervivencia a 7 años libre de enfermedad tras resección completa del tumor primario y resecciones repetidas de recidivas locorregional y a distancia. Revisión a raiz de un caso con una pobre esperanza de vida inicial.
  • OBJECTIVES: We report the case of a female patient with adrenal carcinoma who had undergone surgery and presented with local-regional and distant recurrences, emphasizing the importance of the aggressive surgical treatment to achieve long-term survival which is unexpected sometimes.
  • METHODS/RESULTS: We report the case of a 29-year-old female patient who consulted for left flank pain, being diagnosed of an adrenal tumor by radiological tests; she underwent surgical excision of a left adrenal carcinoma (stage II).
  • Currently, the patient is alive and free of disease 7 years after diagnosis.
  • CONCLUSIONS: Adrenal cancer recurrences have been considered lethal in the short-term.
  • Nevertheless, an aggressive surgical approach of local recurrences and metastasic disease may significantly prolong patient's survival and, sometimes, leave the patient disease free several years after the diagnosis of the primary tumor.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Carcinoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15847268.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


37. Kushner BH, Kramer K, Modak S, Akhurst TJ, Cheung NK: A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy. Pediatr Blood Cancer; 2009 Dec 15;53(7):1340-2
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy.
  • An asymptomatic 11-week-old male received no treatment after he was classified as having a suspected atypical form of MYCN-nonamplified hyperdiploid stage 4S neuroblastoma (NB), with masses in an adrenal gland, subcutaneous tissues, and the falx cerebri.
  • The falx cerebri probably does not represent an atypical site for stage 4S NB, but stage 4 NB with favorable biology is sometimes curable with minimal therapy.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] J Clin Oncol. 2000 Feb;18(3):477-86 [10653863.001]
  • [Cites] Lancet. 2007 Jun 23;369(9579):2106-20 [17586306.001]
  • [Cites] Br J Cancer. 2000 Oct;83(8):973-9 [10993641.001]
  • [Cites] Med Pediatr Oncol. 2000 Dec;35(6):683-7 [11107146.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):470-6 [12888814.001]
  • [Cites] Radiol Med. 1992 Apr;83(4):467-70 [1604008.001]
  • [Cites] Lancet. 1994 Sep 24;344(8926):869-70 [7916408.001]
  • [Cites] Med Pediatr Oncol. 1995 Apr;24(4):257-61 [7700171.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1537-44 [8622069.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Nov;26(11):703-5 [15543002.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Dec;26(12):791-6 [15591897.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6466-73 [16116152.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6474-80 [16116154.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):264-5 [16078224.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):278-84 [16124002.001]
  • [Cites] Semin Pediatr Surg. 2006 Feb;15(1):10-6 [16458841.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Aug;28(8):537-9 [16912596.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1260-8 [10715296.001]
  • (PMID = 19711437.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA106450; United States / NCI NIH HHS / CA / CA106450; United States / FDA HHS / FD / FD-R-001041
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 35MRW7B4AD / 3-Iodobenzylguanidine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS342933; NLM/ PMC4079037
  •  go-up   go-down


38. Kasperlik-Zaluska AA, Cichocki A: Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up. J Exp Ther Oncol; 2005;5(2):125-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.
  • Metastatic or regional stage was diagnosed in 15 patients, while localized disease in three patients.
  • In the group of patients with regional or metastatic stage, both the o,p'-DDE levels and the o,p'-DDE/o,p'-DDD ratios were higher in the survivors than in non-survivors.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Antineoplastic Agents, Hormonal / blood. Mitotane / analogs & derivatives. Mitotane / blood

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471038.001).
  • [ISSN] 1359-4117
  • [Journal-full-title] Journal of experimental therapeutics & oncology
  • [ISO-abbreviation] J. Exp. Ther. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 34113-46-7 / 2,2-(2-chlorophenyl-4'-chlorophenyl)acetic acid; 3424-82-6 / 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene; 78E4J5IB5J / Mitotane
  •  go-up   go-down


39. Ahlborn GJ, Nelson GM, Grindstaff RD, Waalkes MP, Diwan BA, Allen JW, Kitchin KT, Preston RJ, Hernandez-Zavala A, Adair B, Thomas DJ, Delker DA: Impact of life stage and duration of exposure on arsenic-induced proliferative lesions and neoplasia in C3H mice. Toxicology; 2009 Aug 3;262(2):106-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of life stage and duration of exposure on arsenic-induced proliferative lesions and neoplasia in C3H mice.
  • Epidemiological studies suggest that chronic exposure to inorganic arsenic is associated with cancer of the skin, urinary bladder and lung as well as the kidney and liver.
  • To further characterize age susceptibility to arsenic carcinogenesis we administered 85 ppm inorganic arsenic in drinking water to C3H mice during gestation, prior to pubescence and post-pubescence to compare proliferative lesion and tumor outcomes over a one-year exposure period.
  • In contrast, inorganic arsenic significantly decreased the incidence of tumors in liver (0%) and adrenal glands (0%) of male mice continuously exposed from gestation through one year, as compared to levels in control (30 and 65%, respectively) and gestation only (33 and 55%, respectively) exposed mice.
  • Together, these results suggest that continuous inorganic arsenic exposure at 85 ppm from gestation through one year increases the incidence and severity of urogenital proliferative lesions in female mice and decreases the incidence of liver and adrenal tumors in male mice.
  • [MeSH-major] Adrenal Gland Neoplasms / chemically induced. Arsenites / toxicity. Carcinogens / toxicity. Liver Neoplasms / chemically induced. Oviducts / drug effects. Sodium Compounds / toxicity. Urinary Bladder / drug effects

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):920-8 [17565158.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1293-6 [16882542.001]
  • [Cites] Environ Health Perspect. 2007 Oct;115(10):1503-9 [17938743.001]
  • [Cites] PLoS Genet. 2007 Nov;3(11):e207 [18039032.001]
  • [Cites] J Lipid Res. 1999 Sep;40(9):1549-58 [10484602.001]
  • [Cites] Jpn J Cancer Res. 2000 Jun;91(6):579-81 [10874208.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2000;19(3):281-6 [10983894.001]
  • [Cites] Epidemiology. 2000 Nov;11(6):673-9 [11055628.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):249-61 [11312654.001]
  • [Cites] Rev Environ Contam Toxicol. 2001;169:165-214 [11330077.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1387-97 [12151359.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11482-6 [12177411.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1933-6 [12419843.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17 [12583988.001]
  • [Cites] Epidemiology. 2003 Mar;14(2):174-82 [12606883.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):37-65 [14643412.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):466-74 [15026472.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):377-84 [15276417.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):394-404 [15276419.001]
  • [Cites] Environ Health Perspect. 1976 Dec;18:133-9 [1030391.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7677-81 [2174729.001]
  • [Cites] Am J Epidemiol. 1992 Mar 1;135(5):462-76 [1570813.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1296-300 [7882325.001]
  • [Cites] Am J Epidemiol. 1995 Mar 15;141(6):523-30 [7900719.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):209-18 [9219559.001]
  • [Cites] Int J Epidemiol. 1998 Aug;27(4):561-9 [9758107.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1873-6 [10469637.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;84:269-477 [15645578.001]
  • [Cites] Cancer Lett. 2005 Jun 1;223(1):27-35 [15890234.001]
  • [Cites] Toxicol Lett. 2005 Aug 14;158(2):87-94 [16039397.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Oct 15;208(2):186-97 [16183392.001]
  • [Cites] J Agric Food Chem. 2005 Nov 2;53(22):8813-9 [16248589.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2179-86 [16014701.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1337-45 [16452187.001]
  • [Cites] Toxicology. 2006 Jun 1;223(1-2):82-100 [16677751.001]
  • [Cites] Crit Rev Toxicol. 2006 Feb;36(2):99-133 [16736939.001]
  • [Cites] Toxicology. 2006 Jul 5;224(1-2):147-55 [16753250.001]
  • [Cites] Cancer Sci. 2006 Jul;97(7):675-81 [16827809.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Aug 1;222(3):281-8 [17118416.001]
  • (PMID = 19450653.001).
  • [ISSN] 1879-3185
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC005488-22; United States / Intramural NIH HHS / / Z01 BC005488-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Arsenites; 0 / Carcinogens; 0 / Sodium Compounds; 48OVY2OC72 / sodium arsenite
  • [Other-IDs] NLM/ NIHMS127111; NLM/ PMC3496158
  •  go-up   go-down


40. Yamaguchi E, Uchida M, Makino Y, Tachibana M, Sato T, Yamamoto Y, Kawashima K, Araki A, Maruyama R: Tonsillar metastasis of gastric cancer. Clin J Gastroenterol; 2010 Dec;3(6):289-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tonsillar metastasis of gastric cancer.
  • Metastasis from a malignant tumor to the palatine tonsils is rare, with only 100 cases reported in the English-language literature.
  • Tonsillar metastasis from a gastric cancer is very rare.
  • We report here a case of palatine tonsillar metastasis after gastric cancer surgery.
  • The patient was an 88-year-old woman who had gastric cancer with abdominal wall invasion.
  • Histologically, the tumor was primarily a moderately differentiated adenocarcinoma.
  • It was stage IV (T4, N1, M0) using TNM clinical classification.
  • Multiple lung metastases, Virchow's lymph node metastasis, and adrenal metastasis were observed.
  • It was diagnosed as a moderately differentiated adenocarcinoma, a metastasis from gastric cancer.
  • There was a concern of asphyxiation due to hemorrhage of the tumor; however, the tumor dislodged approximately 10 days after biopsy and tonsillar recurrence was not observed.
  • Tonsillar metastasis is a form of systemic metastasis of a malignant tumor, and there is a high risk for asphyxiation from tumor dislodgement or hemorrhage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21841958.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


41. Labrie F: Hormonal therapy of prostate cancer. Prog Brain Res; 2010;182:321-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormonal therapy of prostate cancer.
  • Of all cancers, prostate cancer is the most sensitive to hormones: it is thus very important to take advantage of this unique property and to always use optimal androgen blockade when hormone therapy is the appropriate treatment.
  • Consequently, after castration, the 95-97% fall in serum testosterone does not reflect the 40-50% testosterone (testo) and dihydrotestosterone (DHT) made locally in the prostate from DHEA of adrenal origin.
  • In fact, while elimination of testicular androgens by castration alone has never been shown to prolong life in metastatic prostate cancer, combination of castration (surgical or medical with a gonadotropin-releasing hormone (GnRH) agonist) with a pure anti-androgen has been the first treatment shown to prolong life.
  • Most importantly, when applied at the localized stage, the same combined androgen blockade (CAB) can provide long-term control or cure of the disease in more than 90% of cases.
  • Obviously, since prostate cancer usually grows and metastasizes without signs or symptoms, screening with prostate-specific antigen (PSA) is absolutely needed to diagnose prostate cancer at an 'early' stage before metastasis occurs and the cancer becomes non-curable.
  • While the role of androgens was believed to have become non-significant in cancer progressing under any form of androgen blockade, recent data have shown increased expression of the androgen receptor (AR) in treatment-resistant disease with a benefit of further androgen blockade.
  • While waiting for this (these) new anti-androgen(s), combined treatment with castration and a pure anti-androgen (bicalutamide, flutamide or nilutamide) is the only available and the best scientifically based means of treating prostate cancer by hormone therapy at any stage of the disease with the optimal chance of success and even cure in localized disease.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Hormones.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20541672.001).
  • [ISSN] 1875-7855
  • [Journal-full-title] Progress in brain research
  • [ISO-abbreviation] Prog. Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Androgens; 0 / Anilides; 0 / Hormones; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


42. Pfannschmidt J, Dienemann H: Surgical treatment of oligometastatic non-small cell lung cancer. Lung Cancer; 2010 Sep;69(3):251-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of oligometastatic non-small cell lung cancer.
  • Patients with stage IV metastatic non-small cell lung cancer (NSCLC) are generally believed to have an incurable disease.
  • This article discusses the biology of the oligometastatic state in patients with lung cancer and the selection of patients for surgery, as well as the prognostic factors that influence survival of the patient.
  • Patients with resected brain metastasis achieve 5-year survival rates between 11% and 30%, and those with adrenalectomy for adrenal metastasis achieve 5-year survival rates of 26%.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Brain Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Solitary Pulmonary Nodule / surgery
  • [MeSH-minor] Disease-Free Survival. Humans. Neoplasm Metastasis. Neoplasm Staging. Patient Selection. Prognosis. Survival Rate


43. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, Lee JE: Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol; 2010 Jan;17(1):263-70
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
  • Factors predicting increased risk of recurrence on multivariate analysis were surgery at an outside institution [hazard ratio (HR) 2.56, 95% confidence interval (CI) 1.44-4.53, P = 0.001] and no treatment with adjuvant mitotane (HR 1.95, 95% CI 1.06-3.59, P = 0.03), and those predicting a poorer survival were advanced stage at presentation (P = 0.01) and surgery at an outside institution (HR 2.62, 95% CI 1.31-5.25, P = 0.007).
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851811.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


44. Turkbey B, Basaran C, Karcaaltincaba M, Akpinar E, Oguz B, Akata D, Ozmen MN, Akhan O: Peritoneal carcinomatosis in urinary bladder cancer. Clin Imaging; 2008 May-Jun;32(3):192-5
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis in urinary bladder cancer.
  • PURPOSE: The objective of this study is to describe the computed tomography findings of peritoneal carcinomatosis of urinary bladder cancer.
  • MATERIAL AND METHOD: Patients with urinary bladder cancer were reviewed from patient database of our hospital, and 384 patients with urinary bladder cancer were identified.
  • Computed tomography scans of 105 patients with urinary bladder cancer were retrospectively reviewed.
  • In two patients, liver metastases were detected; additionally, one patient had accompanying pleural implants and one patient had adrenal gland metastases.
  • Peritoneal involvement was detected in the preoperative stage in five patients.
  • CONCLUSION: Presence of peritoneal carcinomatosis in cancer patients is an indicator of poor prognosis.
  • Detection of peritoneal involvement in urinary bladder cancer patients can alter treatment strategy and may prevent unnecessary aggressive surgical interventions.
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Carcinoma / epidemiology. Carcinoma / pathology. Carcinoma / radiography. Carcinoma / surgery. Contrast Media / pharmacology. Female. Follow-Up Studies. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Neoplasm Staging. Radiographic Image Enhancement. Registries. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502346.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


45. Debevec L, Erzen J, Debeljak A, Crnjac A, Kovac V: Exploratory thoracotomy and its influence on the survival of patients with lung cancer. Wien Klin Wochenschr; 2006 Aug;118(15-16):479-84
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploratory thoracotomy and its influence on the survival of patients with lung cancer.
  • PURPOSE: To evaluate diagnostic procedures, reasons for exploratory thoracotomy (ET), causes of unresectability of lung cancer, possibility for reducing numbers of ETs, and the influence of ET on survival.
  • PATIENTS AND METHODS: Between 1990 and 1999, 1808 patients with lung cancer were operated on.
  • The clinical stages were: three patients in stage IA, 28 in IB, one in IIA, 35 in IIB, 50 in IIIA, 10 in IIIB (all due to invasion of the mediastinum), and four patients in IV (three with ipsilateral pulmonary and one with solitary suprarenal metastasis).
  • The control group for calculating survival difference consisted of 130 consecutive non-operated patients with comparable characteristics (age, sex, clinical stage, performance status, histology and comorbidity) who were diagnosed during the period 1996-1998.
  • Clinical and surgical staging were equal in 3% of stage IIB patients, in 24% of stage IIIA, 100% of stage IIIB and 75% of patients in stage IV.
  • The reasons for ET were: diagnosis of preoperatively unverified tumor in one patient, necessity for pneumonectomy in the case of poor pulmonary function in 11 patients, and unresectability in 119 (due to invasion of the mediastinum in 98 patients, thoracic wall in three and vertebral body in one, and due to pleural metastases in 17 patients).
  • [MeSH-minor] Adrenal Gland Neoplasms / secondary. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Lung / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiography, Thoracic. Survival Analysis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957979.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


46. Tanaka T, Sekimura A, Tanaka H, Tonegawa K, Ogawa K, Haneda H: [Gallbladder metastasis of large cell lung cancer]. Kyobu Geka; 2009 Nov;62(12):1069-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gallbladder metastasis of large cell lung cancer].
  • A man, who received right upper lobectomy of the lung due to stage IIB large cell carcinoma 7 and half years ago, visited our hospital complaining of right upper abdominal pain.
  • Computed tomography (CT) revealed gallbladder tumor and extended resection of the gallbladder was performed.
  • Pathological diagnosis was adenosquamous cell carcinoma After 1 year and 4 months later, left adrenal gland tumor was found by CT scan, and the surgery was conducted.
  • Pathologically, it was diagnosed as metastasis from lung cancer.
  • By reevaluation of pathology of the gallbladder, the tumor was found to have similar component of resected lung cancer, suggesting the possibility of the tumor to be metastatic.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894573.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Balogova S, Huchet V, Kerrou K, Nataf V, Gutman F, Antoine M, Ruppert AM, Prignon A, Lavolée A, Montravers F, Mayaud C, Cadranel J, Talbot JN: Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. Nucl Med Commun; 2010 May;31(5):389-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose.
  • AIM: Bronchioloalveolar (BAC) cancer is a source of false-negative F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) results.
  • We carried out this prospective pilot study to evaluate whether FCH PET/CT could detect lung cancer with a BAC component and could be more sensitive than FDG in this aim.
  • RESULTS: Nine patients (12 lesions) presented BAC or adenocarcinoma with BAC features, two patients presented adenocarcinoma without BAC features (five lesions) and four patients presented benign lesions (15 non-malignant sites).
  • For both FCH and FDG, patient-based sensitivity was 78% for detecting cancer with a BAC component and 82% for detecting malignancy.
  • Site-based sensitivity for detecting malignancy was 76 and 75% for detecting cancer with BAC features, for both radiopharmaceuticals.
  • In these early-stage cancers, only one adrenal metastasis was observed that took up FCH and FDG.
  • CONCLUSION: In this population of patients with ground-glass opacities selected on CT suggestive of BAC or with a history of BAC and a recent lung anomaly on CT, FCH detected all malignant lesions with at least a 2.0 cm short axis.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20145579.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / fluorocholine; 0Z5B2CJX4D / Fluorodeoxyglucose F18; N91BDP6H0X / Choline
  •  go-up   go-down


48. Schilling D, Gakis G, Bökeler U, Stenzl A, Kuczyk MA, Merseburger AS: [Secondary hormonal ablation in hormone-independent prostate cancer]. Urologe A; 2009 Feb;48(2):183-8; quiz 189-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Secondary hormonal ablation in hormone-independent prostate cancer].
  • After an average of 18-24 months under androgen suppression therapy, almost all patients with prostate cancer show a PSA progress.
  • At this hormone-independent stage, a PSA regress can be achieved by secondary hormonal manipulation in approximately 50% of patients for 6-12 months before they become hormone-refractory.
  • Inhibition of the adrenal testosterone synthesis by oral administration of ketoconazol can further delay disease progression.
  • Transdermal application of estrogens also allows temporary control of tumor activity by modulating the LHRH and testosterone release as well as directly effecting tumor cell apoptosis.
  • Recent therapeutic modalities as for example somatostatin analogues influence the microenvironment of tumor cells and thereby intensify the effect of anti-tumor therapy.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2167-72 [8229130.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):382-8 [8996165.001]
  • [Cites] Clin Prostate Cancer. 2002 Sep;1(2):81-9 [15046698.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Urologe A. 2008 Oct;47(10):1334-8 [18566791.001]
  • [Cites] Differentiation. 2007 Nov;75(9):871-82 [17924963.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1835-43 [9586898.001]
  • [Cites] J Urol. 1993 Mar;149(3):607-9 [7679759.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1868-75 [8083710.001]
  • [Cites] Eur Urol. 2008 Jan;53(1):68-80 [17920184.001]
  • [Cites] Eur Urol. 2004 May;45(5):581-4; discussion 585 [15082199.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Jun;10(6):1099-115 [11772238.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1025-33 [15020604.001]
  • [Cites] Urologe A. 2005 Nov;44(11):1303-4, 1306-14 [16237541.001]
  • [Cites] Scand J Urol Nephrol. 2002;36(6):405-13 [12623503.001]
  • [Cites] J Cell Biochem. 2006 Aug 15;98(6):1408-23 [16619263.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):286-92 [8772781.001]
  • (PMID = 19214617.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Estrogens
  • [Number-of-references] 18
  •  go-up   go-down


49. Hishida T, Nagai K, Yoshida J, Nishimura M, Ishii G, Iwasaki M, Nishiwaki Y: Is surgical resection indicated for a solitary non-small cell lung cancer recurrence? J Thorac Cardiovasc Surg; 2006 Apr;131(4):838-42
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is surgical resection indicated for a solitary non-small cell lung cancer recurrence?
  • OBJECTIVES: Some investigators have reported long-term survival after surgical resection of a solitary non-small cell lung cancer recurrence in various sites.
  • METHODS: We reviewed 28 patients with a solitary recurrence after successful initial resection of primary non-small cell lung cancer who underwent resection of the recurrent lesion.
  • Recurrence resection was performed for the following sites: 16 in the lung, 5 in the brain, 2 in the adrenal gland, and 1 each in the chest wall, stomach, skin, pelvic lymph node, and malar bone.
  • Advanced p-stage (p-stage II and III, n = 14) of the primary tumor was the significant negative prognostic factor.
  • Patients with p-stage II or III had survival equivalent to that of those who had multiple recurrences or were unfit for further surgical intervention.
  • CONCLUSIONS: Resection of a solitary non-small cell lung cancer recurrence might provide long-term survival in highly selected patients.
  • However, surgical resection might be contraindicated if the primary tumor is stage II or III.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adrenal Gland Neoplasms / mortality. Adrenal Gland Neoplasms / secondary. Adult. Aged. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580442.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Kuczyk M, Wegener G, Jonas U: The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol; 2005 Aug;48(2):252-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer.
  • INTRODUCTION: Solitary adrenal metastases occur in about 1.2-10% of renal cell cancer patients.
  • Since the vast majority of intraadrenal lesions can be detected preoperatively, we and others have recently recommended to renounce a routine adrenalectomy during surgery of renal cell cancer.
  • However, the impact of adrenalectomy on the patients' clinical prognosis in case of a solitary metastatic lesion within the adrenal gland remains an issue of controversial discussion.
  • PATIENTS AND METHOD: Between 1981 and 2000, 648 patients (440 males and 208 females) underwent nephrectomy in combination with adrenalectomy in our clinic for the diagnosis of renal cell cancer.
  • The median age at first diagnosis was 59 (range 33-84) and 60 (range 20-85) years for male and female patients, respectively.
  • According to the TNM - classification system (2003) tumor stages were classified as follows: T1, 228 pat. (37%); T2, 70 pat. (11%); T3, 287 pat. (46%); T4, 37 pat. (6%).
  • Although metastases of the adrenal gland were diagnosed in 48 patients, solitary intraadrenal metastases without further systemic spread were observed in only 13 cases.
  • Several patients' and tumor characteristics (age, tumor stage and size, the presence of regional lymph node metastases, the presence of metastatic lesions at different organ sites as well as the detection of solitary intraadrenal metastases) were correlated with the patients' overall survival by univariate and multivariate statistical analysis (logistic Cox regression analysis).
  • The observation that the long - term survival of the latter patients is comparable to that of patients with organ - confined disease might suggest the establishment of a separate TNM - category for patients revealing a solitary metastasis within the adrenal gland and no hint at further systemic metastatic spread.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Adrenalectomy. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology


51. Quint LE: Staging non-small cell lung cancer. Cancer Imaging; 2007;7:148-59
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging non-small cell lung cancer.
  • Patients with newly diagnosed non-small cell lung cancer (NSCLC) need accurate tumor staging in order to direct appropriate therapy and establish prognosis; the tumor is usually staged using the TNM system.
  • The major imaging modalities currently used for staging this disease are thoracic computed tomography (CT) (including the adrenal glands) and whole body fluorodeoxyglucose (FDG)-positron emission tomography (PET) scanning.
  • CT is generally most useful in evaluating the T stage, i.e. local spread of the neoplasm, whereas PET is most helpful in assessing the N and M stages, i.e. regional and distant tumor spread, respectively.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Neoplasm Staging / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1999 Nov;213(2):530-6 [10551237.001]
  • [Cites] Ann Thorac Surg. 1995 Dec;60(6):1573-81; discussion 1581-2 [8787446.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):245-9 [10882281.001]
  • [Cites] N Engl J Med. 2000 Jul 27;343(4):254-61 [10911007.001]
  • [Cites] Radiology. 2000 Dec;217(3):629-32 [11110922.001]
  • [Cites] Oncol Rep. 2001 Mar-Apr;8(2):337-9 [11182051.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):287-93 [11380213.001]
  • [Cites] J Nucl Med. 2001 Dec;42(12):1795-9 [11752075.001]
  • [Cites] Radiology. 2002 Mar;222(3):629-33 [11867777.001]
  • [Cites] Clin Chest Med. 2002 Mar;23(1):103-21 [11901906.001]
  • [Cites] Lancet. 2002 Apr 20;359(9315):1388-93 [11978336.001]
  • [Cites] Chest. 2002 Dec;122(6):1918-24 [12475827.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2500-7 [12815135.001]
  • [Cites] Ann Intern Med. 2003 Dec 2;139(11):879-92 [14644890.001]
  • [Cites] Chest. 2004 Apr;125(4):1413-23 [15078754.001]
  • [Cites] Ann Thorac Surg. 2004 Sep;78(3):1017-23; discussion 1017-23 [15337041.001]
  • [Cites] Ann Surg. 1968 Feb;167(2):199-203 [5635703.001]
  • [Cites] Cancer Chemother Rep 3. 1973 Mar;4(2):63-7 [4580861.001]
  • [Cites] Chest. 1977 Jun;71(6):725-9 [862442.001]
  • [Cites] J Thorac Cardiovasc Surg. 1981 Sep;82(3):325-33 [7278321.001]
  • [Cites] Chest. 1982 Feb;81(2):203-7 [7056085.001]
  • [Cites] Ann Thorac Surg. 1982 Dec;34(6):684-91 [7149846.001]
  • [Cites] Ann Thorac Surg. 1991 Feb;51(2):182-8 [1846522.001]
  • [Cites] Radiology. 1991 Mar;178(3):705-13 [1847239.001]
  • [Cites] Radiology. 1992 Feb;182(2):319-23 [1732943.001]
  • [Cites] Eur J Cardiothorac Surg. 1992;6(5):238-41 [1610591.001]
  • [Cites] Ann Thorac Surg. 1996 Jul;62(1):246-50 [8678651.001]
  • [Cites] AJR Am J Roentgenol. 1997 May;168(5):1357-60 [9129444.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Aug;12(2):224-7 [9288511.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):286-91 [10024112.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Mar;117(3):593-8 [10047665.001]
  • [Cites] Radiology. 1999 Sep;212(3):803-9 [10478250.001]
  • [Cites] Ann Thorac Surg. 1999 Sep;68(3):1022-8 [10510001.001]
  • [Cites] J Nucl Med. 2004 Dec;45(12):2058-62 [15585482.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):375-82 [15620991.001]
  • [Cites] Chest. 2005 Feb;127(2):438-42 [15705979.001]
  • [Cites] Invest Radiol. 2005 Apr;40(4):204-9 [15770138.001]
  • [Cites] Oncologist. 2005 May;10(5):335-44 [15851792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):170-8 [16111586.001]
  • [Cites] Radiology. 2005 Sep;236(3):1011-9 [16014441.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jan;186(1):130-5 [16357391.001]
  • [Cites] Radiology. 2006 Feb;238(2):578-85 [16371582.001]
  • [Cites] AJR Am J Roentgenol. 2006 Nov;187(5):1303-8 [17056920.001]
  • [Cites] Nucl Med Commun. 2006 Dec;27(12):971-6 [17088683.001]
  • [Cites] Acad Radiol. 2007 Apr;14(4):468-75 [17368217.001]
  • [Cites] J Thorac Oncol. 2007 Jul;2(7):593-602 [17607114.001]
  • [Cites] J Thorac Oncol. 2007 Jul;2(7):603-12 [17607115.001]
  • [Cites] J Thorac Oncol. 2007 Aug;2(8):686-93 [17762334.001]
  • [Cites] J Thorac Oncol. 2007 Aug;2(8):694-705 [17762335.001]
  • [Cites] J Thorac Oncol. 2007 Aug;2(8):706-14 [17762336.001]
  • [Cites] Am J Clin Oncol. 2000 Feb;23(1):47-52 [10683077.001]
  • (PMID = 17964957.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  • [Other-IDs] NLM/ PMC2072091
  •  go-up   go-down


52. Nuver J, Smit AJ, Wolffenbuttel BH, Sluiter WJ, Hoekstra HJ, Sleijfer DT, Gietema JA: The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol; 2005 Jun 1;23(16):3718-25
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer.
  • PURPOSE: The metabolic syndrome may be an important risk factor for cardiovascular disease in long-term survivors of testicular cancer (TC).
  • PATIENTS AND METHODS: We included TC patients cured by orchidectomy and cisplatin-based chemotherapy, stage I TC patients after orchidectomy only, and healthy men of comparable age.
  • RESULTS: Eighty-six chemotherapy patients (median follow-up, 7 years) were compared with 44 stage I patients and 47 controls.
  • Adrenal and thyroid hormone production were unaffected.
  • CONCLUSION: We found gonadal dysfunction, but normal adrenal and thyroid function.

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Jun 1;23(16):3663-5 [15738543.001]
  • (PMID = 15738540.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sex Hormone-Binding Globulin; 3XMK78S47O / Testosterone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


53. Amiri AH, Rafiei A: Analysis of patients with post-chemotherapy arthralgia and arthritis in breast cancer. Indian J Med Sci; 2010 May;64(5):197-203
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of patients with post-chemotherapy arthralgia and arthritis in breast cancer.
  • OBJECTIVE: Evaluate the characteristics of arthropathy and musculoskeletal pain after chemotherapy in patients with breast cancer.
  • MATERIALS AND METHODS: In this study, we evaluate the characteristics of 15 patients with joint symptoms after receiving chemotherapy for breast cancer.
  • RESULTS: Patients comprised 15 women with mean age 43.4 ± 10.6 years that received classic chemotherapy for breast cancer according to stage of disease including cyclophosphamide, and tamoxifen.
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antirheumatic Agents / therapeutic use. Cyclophosphamide / adverse effects. Female. Humans. Middle Aged. Tamoxifen / adverse effects

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22842318.001).
  • [ISSN] 1998-3654
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 094ZI81Y45 / Tamoxifen; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


54. Raynaud JP: Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol; 2006 Dec;102(1-5):261-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer risk in testosterone-treated men.
  • Testosterone replacement therapy is now being prescribed more often for aging men, the same population in which prostate cancer incidence increases; it has been suggested that administration in men with unrecognised prostate cancer might promote the development of clinically significant disease.
  • In hypogonadal men who were candidates for testosterone therapy, a 14% incidence of occult cancer was found.
  • A percentage (15.2%) of prostate cancer has been found in the placebo group (with normal DRE and PSA) in the prostate cancer prevention study investigating the chemoprevention potential of finasteride.
  • The hypothesis that high levels of circulating androgens is a risk factor for prostate cancer is supported by the dramatic regression, after castration, of tumour symptoms in men with advanced prostate cancer.
  • However these effects, seen at a very late stage of cancer development, may not be relevant to reflect the effects of variations within a physiological range at an earlier stage.
  • Data from all published prospective studies on circulating level of total and free testosterone do not support the hypothesis that high levels of circulating androgens are associated with an increased risk of prostate cancer.
  • A study on a large prospective cohort of 10,049 men, contributes to the gathering evidence that the long standing "androgen hypothesis" of increasing risk with increasing androgen levels can be rejected, suggesting instead that high levels within the reference range of androgens, estrogens and adrenal androgens decrease aggressive prostate cancer risk.
  • Indeed, high-grade prostate cancer has been associated with low plasma level of testosterone.
  • Furthermore, pre-treatment total testosterone was an independent predictor of extraprostatic disease in patients with localized prostate cancer; as testosterone decreases, patients have an increased likelihood of non-organ confined disease and low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy.
  • During the clinical development of a new testosterone patch in more than 200 primary or secondary hypogonadal patients, no prostate cancer was diagnosed.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17113983.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens; 3XMK78S47O / Testosterone
  • [Number-of-references] 36
  •  go-up   go-down


55. Russo P, Synder M, Vickers A, Kondagunta V, Motzer R: Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. ScientificWorldJournal; 2007;7:768-78
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer.
  • Between July 1989 and September 2003, we queried our department's renal tumor database for patients undergoing cytoreductive nephrectomy alone or in conjunction with complete metastasectomy.
  • Clinical and pathological factors analyzed included primary tumor size, stage and histological subtype, age, gender, Karnofsky Performance Status (KPS) prior to nephrectomy, number and location of metastatic sites, and the presence or absence of any systemic therapy.
  • Sixty-four percent of patients had a single site of metastatic disease, with lung the most common, followed by bone, adrenal, brain, and liver.
  • For patients with metastatic renal cell carcinoma, surgical resection of the primary tumor alone (cytoreductive nephrectomy) or in conjunction with metastasectomy can be accomplished with acceptable perioperative morbidity and mortality.
  • This surgical experience provides a contemporary foundation as new targeted therapeutic agents are integrated into the neoadjuvant or adjuvant treatment of locally advanced and metastatic renal cancer.
  • [MeSH-major] Kidney Neoplasms / mortality. Kidney Neoplasms / surgery. Neoplasm Metastasis / prevention & control. Nephrectomy / mortality. Risk Assessment / methods


56. Lee SE, Jeon EJ, Oh JH, Shim KH, Lee J, Kim EH, Choi SW, Min KO: [A case of advanced gastric cancer with perianal skin metastasis]. Korean J Gastroenterol; 2008 Jan;51(1):40-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with perianal skin metastasis].
  • The most common metastatic sites of gastric cancer are liver, lung, bone and adrenal gland.
  • However, skin metastases from gastric cancer are relatively rare.
  • We herein report a case of advanced gastric cancer with perianal skin metastasis in a 70-year-old male.
  • Endoscopy and abdominal CT scan demonstrated the stage IV gastric cancer.
  • We suspected that the perianal lesion was originated from gastric cancer.
  • [MeSH-major] Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged. Anal Canal. Humans. Male. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349561.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


57. Cardinale L, Cortese G, Borasio P, Dogliotti L, Ferraris F, Novello S, Perotto F, Scagliotti G, Fava C: Low dose CT in early lung cancer diagnosis: Prevalence data. Radiol Med; 2005 Nov-Dec;110(5-6):532-43
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low dose CT in early lung cancer diagnosis: Prevalence data.
  • PURPOSE: Lung cancer has a high mortality rate and its prognosis largely depends on early detection.
  • We report the prevalence data of the study on early detection of lung cancer with low-dose spiral CT underway at our hospital.
  • Six cases of lung cancer were identified, of which four were stage I, one stage was IIIB and one was stage IV with adrenal metastases.
  • CONCLUSIONS: Our preliminary data on spiral CT as a potential new diagnostic tool for lung cancer screening, although less promising than the Japanese and ELCAP results, confirm the feasibility of the technique.
  • [MeSH-minor] Early Diagnosis. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prevalence. Radiation Dosage. Smoking

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437039.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


58. Nakagawa H, Yamamoto K: [A case of small cell lung cancer complicated by Cushing syndrome]. Nihon Kokyuki Gakkai Zasshi; 2008 Mar;46(3):210-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of small cell lung cancer complicated by Cushing syndrome].
  • After a systemic examination, Stage IV small cell lung cancer with Cushing's syndrome was diagnosed.
  • Marked increases in ACTH levels were observed, but no abnormality was found in the pituitary MRI findings, and therefore ACTH-producing small cell lung cancer was suspected.
  • The tumor temporarily began to decrease in size, but hypercortisolemia remained, and thus adrenal hormone synthesis-inhibiting therapy was concurrently administered.
  • Hypercortisolemia is believed to induce the suppression of the immune system, thereby affecting the outcome and QOL more than the immediate symptoms of cancer.
  • Therefore, from an early stage, it is believed that adrenal cortical hormone synthesis-inhibiting therapy should be performed concurrently with chemotherapy, if hypercortisolemia cannot be controlled by radiation and chemotherapy alone.

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409568.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


59. Akaza H, Labrie F, Namiki M: [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation]. Gan To Kagaku Ryoho; 2007 Apr;34(4):657-69
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation].
  • The MAB (Maximal Androgen Blockade) therapy is a treatment to exert maximal effects of hormone therapy, inhibiting androgen activity derived from both testes and adrenal gland that promotes proliferation of prostate cancer, being proposed by Dr.
  • For efficacy of the MAB therapy, a meta-analysis of randomized control studies with metastatic prostate cancer realized primarily in Europe and America showed the survival benefit of MAB therapy using nonsteroidal antiandrogen agent, which have placed it as a standard therapy for metastatic prostate cancer.
  • However, it was suggested that the better effect of MAB therapy was expected in patients without distant metastasis rather than patients with metastatic prostate cancer, and it was noted that the time to progression (TTP) was significantly improved in patients of stage C in a randomized double-blind control study on bicalutamide+LH-RH agonist vs. placebo+LH-RH agonist conducted in Japan.
  • Labrie et al. suggested that the patients where the cure was expected did exist by continuing long-term MAB therapy against local prostate cancer.
  • Labrie, the importance of MAB therapy among the hormone therapy against prostate cancer, the possibility of MAB therapy as a curative treatment against local/locally advanced prostate cancer and the ideal way of application of hormone therapy were discussed, and the significance was showed to conduct a most effective hormone therapy (MAB therapy) in earlier stage where the androgen sensitivity was noted.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431361.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Conference; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


60. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B, German Adrenocortical Carcinoma Registry Group, European Network for the Study of Adrenal Tumors: Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer; 2009 Jan 15;115(2):243-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is a rare malignancy, and it was only in 2004 that the International Union Against Cancer (UICC) defined TNM criteria and published the first staging classification.
  • METHODS: The German ACC Registry comprising 492 patients was searched for patients who were diagnosed between 1986 and 2007 with detailed information on primary diagnosis and a minimum follow-up of 6 months.
  • Patients were assigned to UICC tumor stage, and disease-specific survival (DSS) was assessed.
  • RESULTS: In total, 416 patients with a mean follow-up of 36 months met the inclusion criteria (stage I, n=23 patients; stage II, n=176 patients; stage III, n=67 patients; stage IV, n=150 patients).
  • Kaplan-Meier analysis revealed a stage-dependent DSS.
  • However, DSS in patients with stage II ACC did not differ significantly from DSS in patients with stage III ACC (hazard ratio, 1.38; 95% confidence interval, 0.89-2.16).
  • Furthermore, patients who had stage IV ACC without distant metastases had an improved DSS compared with patients who had metastatic disease (P=.004).
  • An analysis of different potential risk factors for defining stage III ACC revealed important roles in DSS for tumor infiltration in surrounding tissue, venous tumor thrombus (VTT), and positive lymph nodes; whereas tumor invasion in adjacent organs carried a prognosis similar to that of infiltration in surrounding tissue only.
  • On the basis of the current analysis, a revised classification with superior prognostic accuracy is proposed (the European Network for the Study of Adrenal Tumors classification).
  • In this system, stage III ACC is defined by the presence of positive lymph nodes, infiltration of surrounding tissue, or VTT; and stage IV ACC is restricted to patients with distant metastasis.
  • [MeSH-major] Adrenocortical Carcinoma / pathology. Neoplasm Staging / classification
  • [MeSH-minor] Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • [CommentIn] Cancer. 2009 Dec 15;115(24):5847; author reply 5848 [19827149.001]
  • (PMID = 19025987.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Allolio B; Behrend M; Bucsky P; Brauckhoff M; Fasanacht M; Fottner C; Haaf M; Hahner S; Johanssen S; Koschker AC; Langer P; Laubner K; Linden T; Maeder U; Morcos M; Oelkers W; Quinkler M; Reincke M; Reisch N; Saeger W; Weismann D; Willenberg HS; Wortmann S; Baudin E; Bertherat J; Beuschlein F; Mannelli M; Terzolo M
  •  go-up   go-down


61. Huang TW, Tzao C, Chen DW, Tsai WC, Cheng YL, Lee SC: Lung cancer with isolated skip metastasis to an abdominal lymph node. Onkologie; 2007 Jul;30(7):375-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer with isolated skip metastasis to an abdominal lymph node.
  • BACKGROUND: Lung cancer is usually diagnosed at an advanced stage with metastases present in 40% of patients.
  • The preferential sites of extrapulmonary spread include lymph nodes, liver, brain, adrenal gland, and bone.
  • With the advent of PET computed tomography (PET-CT) and its use as a standard pre-operative staging modality for lung cancer, one should anticipate an increased incidence of skip metastasis.
  • [MeSH-minor] Abdomen. Biopsy. Female. Fluorodeoxyglucose F18. Humans. Incidental Findings. Lung / pathology. Lung / radionuclide imaging. Lymph Node Excision. Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2007 Jul;30(7):352 [17596742.001]
  • [CommentIn] Onkologie. 2008 Dec;31(12):708 [19060511.001]
  • (PMID = 17596746.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


62. Ficarra V, Novara G, Iafrate M, Cappellaro L, Bratti E, Zattoni F, Artibani W: Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. Eur Urol; 2007 Mar;51(3):722-9; discussion 729-31
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome.
  • OBJECTIVES: The optimal stratification of locally advanced renal cell carcinoma (RCC) is controversial, with the prognostic relevance of ipsilateral adrenal gland invasion and cranial extension of vena cava thrombosis being the most debatable issues.
  • RESULTS: At a median follow-up of 29 mo, we censored 108 (47.6%) cancer-related deaths.
  • On univariate analysis, the 2002 T stage was not statistically significant.
  • According to cancer-related outcome, we identified three subgroups of patients with different prognoses: pT3a(n): tumors with perirenal fat invasion or renal vein thrombosis or thrombosis within the vena cava below the diaphragm; pT3b(n): tumors with renal vein thrombosis or thrombosis within the vena cava below the diaphragm and concomitant perirenal fat invasion; pT4(n): adrenal gland or Gerota fascia invasion or thrombosis within the vena cava above the diaphragm.
  • The new reclassification was an independent predictive variable on multivariate analysis, as well as the pathologic lymph node stage.
  • The present study suggests the possibility of reclassifying pT3-4 RCC into three categories capable of predicting cancer-specific survival, regardless of all other prognostic factors.
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging / classification. Survival Rate


63. Li J, Ma S, Kang S, Xie J, Sheng X, Luo R: [Evaluation on survival in locally advanced non-small cell lung cancer (NSCLC) for multimodality treatment with or without operation]. Zhongguo Fei Ai Za Zhi; 2005 Dec 20;8(6):535-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation on survival in locally advanced non-small cell lung cancer (NSCLC) for multimodality treatment with or without operation].
  • BACKGROUND: It is uncertain that the effect of multimodality treatment with operation on survival for locally advanced non-small cell lung cancer (NSCLC).
  • Arm A (n=56): 39 cases were at stage IIIA, and 17 at stage IIIB; Median KPS was 80 (range from 70 to 90 ); Multimodality treatment program included operation, chemotherapy, radiotherapy and traditional Chinese herb medicine.
  • Arm B (n=58): 23 cases were at stage IIIA, and 35 at stage IIIB; Median KPS was 70 (range from 60 to 90); Treatment program was the same approximately as arm A except for no operation.
  • (1) Metastatic locations in follow-up, in turn, showed as: lymph node, pleural-lung, bone, brain, liver, pericardium, skin and adrenal;.
  • (1) Metastatic locations in follow-up, in turn, showed as: lymph node, pleural-lung, bone, brain, liver, pericardium, skin, adrenal, pancreatic and esophageal metastasis;.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21208544.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


64. Schilling D, Küfer R, Kruck S, Stenzl A, Kuczyk MA, Merseburger AS: [Somatostatin analogs for the treatment of advanced, hormone-refractory prostate cancer: a possibility for secondary hormonal ablation?]. Urologe A; 2008 Oct;47(10):1334-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Somatostatin analogs for the treatment of advanced, hormone-refractory prostate cancer: a possibility for secondary hormonal ablation?].
  • Almost all patients with hormone-refractory prostate cancer under primary androgen deprivation therapy will develop progression, frequently initially marked by an asymptomatic increase of prostate-specific antigen (PSA).
  • Recent data showed that taxane-based chemotherapy offers significant survival benefit to patients with advanced prostate cancer; however, the toxic side effects frequently exert a significant negative impact on the quality of life.
  • At the androgen-independent stage of the cancer, before becoming hormone refractory, progression might still be delayed by secondary manipulation of either androgen or confounding receptors and their signaling pathways.
  • Secondary hormonal manipulations traditionally included antiandrogen withdrawal, second-line antiandrogens, direct adrenal androgen inhibitors, estrogens, and progestins.We discuss the mode of action and application of somatostatin analogs as an emerging secondary hormonal treatment concept in patients with advanced prostate cancer on the basis of the current literature.
  • [MeSH-minor] Androgen Antagonists / administration & dosage. Apoptosis / drug effects. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Cell Proliferation / drug effects. Disease Progression. Humans. Male. Neoplasm Staging. Prostate-Specific Antigen / drug effects. Survival Rate

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2007 May;30(5):1173-9 [17390019.001]
  • [Cites] Acta Urol Belg. 1994 Apr;62(1):83-8 [7515212.001]
  • [Cites] Br J Cancer. 1998;77(1):115-22 [9459155.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 1):1775-83 [15540720.001]
  • [Cites] Anticancer Res. 1996 Sep-Oct;16(5A):2773-80 [8917385.001]
  • [Cites] Gastroenterol Clin Biol. 2001 Dec;25(12 ):1108-11 [11910994.001]
  • [Cites] Mol Endocrinol. 2007 Oct;21(10):2565-78 [17609435.001]
  • [Cites] Prostate. 1999 Mar 1;38(4):313-6 [10075011.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2731-4 [7872709.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Mol Cell Endocrinol. 2008 May 14;286(1-2):69-74 [17977644.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1028:361-74 [15650261.001]
  • [Cites] Prostate. 2002 Sep 15;53(1):50-9 [12210479.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2643-55 [7595719.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(3):259-62 [7540120.001]
  • [Cites] J Endocrinol Invest. 2004 Jun;27(6):613-4 [15717663.001]
  • [Cites] Urology. 2004 Jan;63(1):120-5 [14751362.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4398-405 [15240528.001]
  • [Cites] Eur Urol. 2008 Jan;53(1):37-44 [17826892.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2159-64 [7535186.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):707-16 [11980628.001]
  • [Cites] Mol Med. 2000 Apr;6(4):251-67 [10949907.001]
  • [Cites] Urologe A. 2005 Nov;44(11):1303-4, 1306-14 [16237541.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Aug;10(8):1521-30 [11772267.001]
  • [Cites] Eur Urol. 2007 Aug;52(2):464-8 [17116360.001]
  • [Cites] J Urol. 2003 Nov;170(5):1812-6 [14532782.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Sep;80(9):2806-14 [7673428.001]
  • [Cites] Scand J Urol Nephrol. 2006;40(5):423-5 [17060090.001]
  • (PMID = 18566791.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents; 51110-01-1 / Somatostatin; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


65. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol; 2009 Aug 10;27(23):3742-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
  • PURPOSE: It has been postulated that castration-resistant prostate cancer (CRPC) commonly remains hormone dependent.
  • PATIENTS AND METHODS: This was a phase I/II study of abiraterone acetate in castrate, chemotherapy-naive CRPC patients (n = 54) with phase II expansion at 1,000 mg (n = 42) using a two-stage design to reject the null hypothesis if more than seven patients had a prostate-specific antigen (PSA) decline of > or = 50% (null hypothesis = 0.1; alternative hypothesis = 0.3; alpha = .05; beta = .14).
  • Computed tomography scans every 12 weeks and circulating tumor cell (CTC) enumeration were performed.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Androstenols / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Drug Resistance, Neoplasm. Enzyme Inhibitors / therapeutic use. Neoplasms, Hormone-Dependent / drug therapy. Prostatic Neoplasms / drug therapy. Steroid 17-alpha-Hydroxylase / antagonists & inhibitors
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Aged. Aged, 80 and over. Androstenes. Disease Progression. Drug Administration Schedule. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prospective Studies. Prostate-Specific Antigen / blood. Testosterone / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Oct;56(4):744-5 [19995526.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6302-9 [18829513.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2030-7 [17404083.001]
  • [Cites] J Steroid Biochem. 1989 Dec;33(6):1191-5 [2559252.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2317-25 [15150570.001]
  • [Cites] BJU Int. 2008 Feb;101(4):440-3 [17941935.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1148-59 [18309951.001]
  • [Cites] J Urol. 2002 Aug;168(2):542-5 [12131305.001]
  • [Cites] J Med Chem. 1990 Nov;33(11):3050-5 [2231604.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):516-21 [16622120.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6407-15 [18676866.001]
  • [Cites] J Urol. 1997 Apr;157(4):1204-7 [9120902.001]
  • [Cites] J Med Chem. 1990 Sep;33(9):2452-5 [2391687.001]
  • [Cites] Stat Med. 1992 May;11(7):853-62 [1604065.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3461-7 [10550143.001]
  • [Cites] Urol Oncol. 2001 May;6(3):111-115 [11344001.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):440-8 [14760063.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Dec 1;75(1):1-10 [11179903.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):257-62 [17235043.001]
  • [Cites] J Med Chem. 1995 Jun 23;38(13):2463-71 [7608911.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4563-71 [18645193.001]
  • [Cites] Eur Urol. 2004 May;45(5):581-4; discussion 585 [15082199.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1440-50 [10735891.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6897-904 [15501967.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1241-6 [16287438.001]
  • [Cites] J Urol. 2005 Mar;173(3):790-6 [15711271.001]
  • [Cites] J Steroid Biochem Mol Biol. 1994 Sep;50(5-6):267-73 [7918112.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2673-8 [12860943.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7053-8 [18056182.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1025-33 [15020604.001]
  • [Cites] Cytometry. 2002 Apr 1;47(4):248-55 [11933015.001]
  • [Cites] Clin Invest Med. 1982;5(4):267-75 [6819101.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4447-54 [18519708.001]
  • [Cites] J Steroid Biochem. 1988 Nov;31(5):845-52 [2462135.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):27-33 [18695026.001]
  • [Cites] Anticancer Drug Des. 1988 Dec;3(3):185-90 [3264700.001]
  • [Cites] CA Cancer J Clin. 2002 May-Jun;52(3):154-79 [12018929.001]
  • [Cites] Lancet. 2000 Apr 29;355(9214):1491-8 [10801170.001]
  • (PMID = 19470933.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / ; United Kingdom / Cancer Research UK / / CRUK/ A7851; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / / C51/A7401; United Kingdom / Medical Research Council / / MRC/ G0501019
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Androgen Antagonists; 0 / Androstenes; 0 / Androstenols; 0 / Antineoplastic Agents, Hormonal; 0 / Enzyme Inhibitors; 3XMK78S47O / Testosterone; EC 1.14.14.19 / Steroid 17-alpha-Hydroxylase; EC 3.4.21.77 / Prostate-Specific Antigen; G819A456D0 / abiraterone
  • [Other-IDs] NLM/ EMS28710; NLM/ PMC3535569
  •  go-up   go-down


66. Iyoda A, Moriya Y, Hiroshima K, Shibuya K, Yoshino I: Successful management of postoperative acute respiratory distress syndrome in a patient with lung cancer. Gen Thorac Cardiovasc Surg; 2008 Jul;56(7):354-6
Hazardous Substances Data Bank. GLYCINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful management of postoperative acute respiratory distress syndrome in a patient with lung cancer.
  • Acute respiratory distress syndrome after pulmonary resection for lung cancer frequently has a lethal outcome.
  • A 74-year-old man was diagnosed with lung cancer and referred to the outpatient department of Chiba University Hospital with double primary lung cancers located in the right upper lobe that were staged at T2N0M0 (stage IB).
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Glycine / analogs & derivatives. Lung Neoplasms / surgery. Pneumonectomy / adverse effects. Proteinase Inhibitory Proteins, Secretory / therapeutic use. Respiratory Distress Syndrome, Adult / drug therapy. Sulfonamides / therapeutic use

  • Genetic Alliance. consumer health - Acute Respiratory Distress Syndrome.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607685.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Proteinase Inhibitory Proteins, Secretory; 0 / Sulfonamides; DWI62G0P59 / sivelestat; TE7660XO1C / Glycine
  •  go-up   go-down


67. Eloubeidi MA, Cerfolio RJ, Chen VK, Desmond R, Syed S, Ojha B: Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans. Ann Thorac Surg; 2005 Jan;79(1):263-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans.
  • BACKGROUND: The treatment of patients with non-small cell lung cancer (NSCLC) depends on the stage.
  • The reference standard included thoracotomy with complete lymphadenectomy in patients with lung cancer or if EUS-FNA was benign, repeat clinical imaging, or long-term follow-up.
  • RESULTS: There were 104 patients (63 men) with 125 lesions (117 lymph nodes, 8 left adrenal glands) who underwent EUS-FNA.
  • EUS-FNA was more accurate and had a higher positive predictive value than the PET or CT (p < 0.001) scan in confirming cancer in the posterior mediastinal lymph nodes.
  • EUS-FNA documented metastatic cancer to the left adrenal in all 4 patients with advanced disease.
  • [MeSH-major] Biopsy, Fine-Needle. Carcinoma, Non-Small-Cell Lung / secondary. Esophagoscopy. Lung Neoplasms / pathology. Lymphatic Diseases / pathology. Lymphatic Metastasis / pathology. Neoplasm Staging / methods. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonography, Interventional
  • [MeSH-minor] Aged. Breast Neoplasms / pathology. Carcinoma / pathology. Carcinoma / radiography. Carcinoma / radionuclide imaging. Carcinoma / secondary. Carcinoma / ultrasonography. Colonic Neoplasms / pathology. Endometrial Neoplasms / pathology. Female. Fluorodeoxyglucose F18. Granuloma / diagnosis. Histiocytosis / complications. Histiocytosis / diagnosis. Histoplasmosis / complications. Histoplasmosis / diagnosis. Humans. Kidney Neoplasms / pathology. Lung Diseases / complications. Lymphoma / pathology. Lymphoma / radiography. Lymphoma / radionuclide imaging. Lymphoma / ultrasonography. Male. Mediastinum. Middle Aged. Predictive Value of Tests. Prospective Studies. Radiopharmaceuticals. Sarcoidosis / complications. Sarcoidosis / diagnosis. Silicosis / complications. Silicosis / diagnosis. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620955.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


68. Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers JS: Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer; 2008 Jan;9(1):30-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can positron emission tomography be used as a staging tool for small-cell lung cancer?
  • PURPOSE: Positron emission tomography (PET) is widely used for the staging evaluation of non-small-cell lung cancer; however, its use in small-cell lung cancer (SCLC) remains investigational.
  • CONCLUSION: Positron emission tomography is potentially useful for accurate initial staging of SCLC and can ensure that a patient's disease is not overstaged by CT scan, which might result in denied potentially curative treatment for limited-stage SCLC.
  • It can identify the occult adrenal metastasis and metastasis to supraclavicular lymph nodes that are missed by CT; however, brain lesions are difficult to assess by PET.
  • [MeSH-minor] Humans. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18282355.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Eisen T, Thatcher N, Leyvraz S, Miller WH Jr, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M: Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer; 2009 Apr;64(1):60-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
  • OBJECTIVE: To evaluate the antitumor activity and safety profile of plitidepsin administered as a 1h weekly intravenous (i.v.) infusion of 3.2mg/m(2) to patients with small cell lung cancer (SCLC) who relapsed or progressed after one line of chemotherapy.
  • Toxicity was assessed using National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0.
  • RESULTS: Twenty pretreated SCLC patients (median age, 60 years) with extensive (n = 13) or limited-stage disease (n = 7) received a total of 24 treatment cycles (median, one cycle per patient; range, 1-2).
  • Objective tumor responses were not observed and only one of the 17 evaluable patients had SD.
  • [MeSH-minor] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / secondary. Adult. Aged. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Female. Humans. Infusions, Intravenous. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Salvage Therapy. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692272.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Depsipeptides; Y76ID234HW / aplidine
  •  go-up   go-down


70. Herndon JE 2nd, Kornblith AB, Holland JC, Paskett ED: Patient education level as a predictor of survival in lung cancer clinical trials. J Clin Oncol; 2008 Sep 1;26(25):4116-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient education level as a predictor of survival in lung cancer clinical trials.
  • PURPOSE: To investigate the effect of socioeconomic status, as measured by education, on the survival of 1,577 lung cancer patients treated on 11 studies conducted by the Cancer and Leukemia Group B.
  • RESULTS: The patient population included 1,177 patients diagnosed with non-small-cell lung cancer (NSCLC; stage III or IV) and 400 patients diagnosed with small-cell lung cancer (SCLC; extensive or limited).
  • Significant predictors of poor survival in the final model included male sex, PS of 1 or 2, dyspnea, weight loss, liver or bone metastases, unmarried, presence of adrenal metastases and high alkaline phosphatase levels among patients with NSCLC, and high WBC levels among patients with advanced disease.
  • Once enrolled onto a clinical trial, education does not affect the survival of patients with SCLC or stage III or IV NSCLC.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Dec 1;86(11):2229-37 [10590362.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1693-6 [14583771.001]
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):861-8 [10737287.001]
  • [Cites] BMJ. 2000 Apr 29;320(7243):1200-4 [10784551.001]
  • [Cites] Cancer. 2001 Jan 1;91(1 Suppl):208-16 [11148581.001]
  • [Cites] BMJ. 2001 May 19;322(7296):1233-6 [11358781.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):284-90 [11854390.001]
  • [Cites] Health Aff (Millwood). 2002 Mar-Apr;21(2):31-46 [11900185.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):101-11 [11936816.001]
  • [Cites] Qual Life Res. 2002 May;11(3):235-48 [12074261.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4191-8 [12377962.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):1988-99 [12404294.001]
  • [Cites] Ann Epidemiol. 2003 Jan;13(1):32-41 [12547483.001]
  • [Cites] Cancer. 2003 May 15;97(10):2480-6 [12733147.001]
  • [Cites] Soc Sci Med. 2003 Dec;57(12):2265-79 [14572836.001]
  • [Cites] J Clin Epidemiol. 2004 Jun;57(6):597-609 [15246128.001]
  • [Cites] Science. 1988 Jul 29;241(4865):540-5 [3399889.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1500-9 [2072149.001]
  • [Cites] Cancer Invest. 1994;12(3):273-82 [8187005.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1113-20 [8201372.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1871-9 [7636529.001]
  • [Cites] Milbank Q. 1996;74(2):215-38 [8632735.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1031-8 [8683633.001]
  • [Cites] J Clin Epidemiol. 1996 Oct;49(10):1155-60 [8826996.001]
  • [Cites] Prostate. 1996 Nov;29(5):271-81 [8898999.001]
  • [Cites] Soc Sci Med. 1997 Mar;44(6):901-10 [9080570.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1680-9 [9193369.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):333-40 [10023700.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):4-11 [10458211.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):190-6 [15625373.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):81-90 [15685040.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1099-104 [15781105.001]
  • [Cites] Med Sci Monit. 2005 May;11(5):RA163-172 [15874907.001]
  • [Cites] Clin Lung Cancer. 2005 Jul;7(1):47-53 [16098244.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):407-12 [16365181.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1245-52 [16670704.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):278-84 [16434087.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):944-9 [16969351.001]
  • [Cites] Haematologica. 2006 Oct;91(10):1410-3 [16963396.001]
  • [Cites] Am J Epidemiol. 2007 Jul 1;166(1):71-8 [17426038.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1532-41 [17702091.001]
  • [Cites] Lung Cancer. 2000 Apr;28(1):63-8 [10704711.001]
  • (PMID = 18757325.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA77651; United States / NCI NIH HHS / CA / CA77658
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2654374
  •  go-up   go-down


71. Degraff DJ, Aguiar AA, Sikes RA: Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res; 2009 Jan 20;1(2):115-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.
  • Accumulating evidence indicates that alterations in the IGF axis contribute to the development of chemo- and radio-resistant, advanced-stage cancers.
  • Increased expression of insulin-like growth factor binding protein 2 (IGFBP-2) is found in advanced cancers of the ovary, breast, stomach, adrenal gland, bladder, CNS, and prostate.
  • Further, IGFBP-2 seemingly has ligand-independent effects that participate in the development and dissemination of advanced cancer cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bull N Y Acad Med. 1963 Nov;39:752-7 [14057738.001]
  • [Cites] J R Coll Surg Edinb. 1959 Apr;4(3):191-8 [13655261.001]
  • [Cites] J Natl Cancer Inst. 1954 Aug;15(1):1-25 [13233864.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Oct 5;263(3):786-9 [10512758.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(1):1-10 [10517338.001]
  • [Cites] Mol Cell Endocrinol. 1998 Mar 16;138(1-2):151-61 [9685224.001]
  • [Cites] J Biol Chem. 1999 Mar 12;274(11):6935-45 [10066747.001]
  • [Cites] J Clin Invest. 1997 Nov 15;100(10):2596-605 [9366575.001]
  • [Cites] Endocrinology. 1997 Oct;138(10):4181-90 [9322928.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3783-92 [8855838.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jul;81(7):2653-62 [8675593.001]
  • [Cites] Biochim Biophys Acta. 1996 Aug 21;1313(1):79-88 [8781553.001]
  • [Cites] Int J Urol. 1996 Jan;3(1):39-46 [8646598.001]
  • [Cites] Mol Endocrinol. 1995 Jul;9(7):902-12 [7476972.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5485-92 [7588299.001]
  • [Cites] Eur J Endocrinol. 1996 Apr;134(4):474-80 [8640300.001]
  • [Cites] Prog Growth Factor Res. 1995;6(2-4):357-66 [8817679.001]
  • [Cites] J Biol Chem. 1995 Sep 1;270(35):20424-31 [7544787.001]
  • [Cites] Endocrinology. 1995 Apr;136(4):1374-80 [7534697.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Mar;80(3):987-93 [7533776.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3732-7 [7518344.001]
  • [Cites] Endocrinology. 1995 Oct;136(10):4168-73 [7545099.001]
  • [Cites] Endocrinology. 1995 Apr;136(4):1403-10 [7534698.001]
  • [Cites] Prostate. 1995 Feb;26(2):72-9 [7531847.001]
  • [Cites] Endocrinology. 1995 Sep;136(9):4049-55 [7544275.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1410-5 [7525636.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6563-70 [7527300.001]
  • [Cites] Int J Cancer. 1994 May 15;57(4):491-7 [7514152.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Mar;78(3):778-83 [7510307.001]
  • [Cites] Endocrinology. 1994 Jan;134(1):126-32 [7506203.001]
  • [Cites] Mol Cell Endocrinol. 1994 Mar;99(2):211-20 [8206329.001]
  • [Cites] J Cell Physiol. 1993 Jun;155(3):556-67 [7684042.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Apr;76(4):1031-5 [7682560.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jul;77(1):229-33 [7686915.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26045-8 [7504671.001]
  • [Cites] Endocrinology. 1993 Mar;132(3):1176-83 [7679972.001]
  • [Cites] Endocrinology. 1993 Sep;133(3):1462-5 [7689959.001]
  • [Cites] J Cell Biol. 1993 May;121(3):679-87 [7683690.001]
  • [Cites] J Biol Chem. 1992 Jun 25;267(18):12692-9 [1377672.001]
  • [Cites] J Biol Chem. 1992 Nov 5;267(31):22467-72 [1385400.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Oct;75(4):1046-53 [1383255.001]
  • [Cites] J Biol Chem. 1992 Jun 15;267(17):11949-56 [1376315.001]
  • [Cites] J Biol Chem. 1992 Oct 15;267(29):21033-7 [1328218.001]
  • [Cites] Breast Cancer Res Treat. 1992;22(1):39-45 [1421423.001]
  • [Cites] Cell Growth Differ. 1991 Sep;2(9):457-64 [1661135.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Aug 30;179(1):378-85 [1652955.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1149-56 [16729015.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24588-601 [16793770.001]
  • [Cites] J Mol Endocrinol. 2006 Aug;37(1):13-23 [16901920.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):1-22 [16844299.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1529-35 [16884361.001]
  • [Cites] Growth Horm IGF Res. 2006 Jun;16(3):202-10 [16844395.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6570-8 [16818629.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):193-200 [16773200.001]
  • [Cites] Genome Res. 2006 Jun;16(6):693-701 [16741161.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2002 Sep;16(3):433-47 [12464227.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1361-8 [12433712.001]
  • [Cites] J Endocrinol. 2002 Oct;175(1):19-31 [12379487.001]
  • [Cites] Endocrinology. 2002 Oct;143(10):3897-904 [12239101.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):705-12 [12163322.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1099-106 [12122101.001]
  • [Cites] Prostate. 2002 Aug 1;52(3):173-82 [12111694.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):972-80 [12096082.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2693-9 [12072403.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):389-96 [12044015.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10489-97 [11784719.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):833-41 [11821468.001]
  • [Cites] Urology. 2001 Oct;58(4):614-8 [11597555.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6276-80 [11507082.001]
  • [Cites] Med Hypotheses. 2001 Feb;56(2):213-6 [11425289.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):1942-52 [11344189.001]
  • [Cites] Endocrinology. 2001 Apr;142(4):1652-8 [11250947.001]
  • [Cites] Urology. 2001 Mar;57(3):471-5 [11248622.001]
  • [Cites] Eur J Endocrinol. 2001 Jan;144(1):29-36 [11174834.001]
  • [Cites] J Clin Invest. 2001 Jan;107(1):73-81 [11134182.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2000 Nov;46(7):1173-82 [11075947.001]
  • [Cites] Int J Urol. 2000 Sep;7(9):321-9 [11020056.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 6;92(23):1910-7 [11106682.001]
  • [Cites] Growth Horm IGF Res. 2000 Apr;10 Suppl A:S30-1 [10984283.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600 [11018095.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Jun;278(6):E967-76 [10826997.001]
  • [Cites] Growth Horm IGF Res. 1998 Jun;8(3):185-93 [10984306.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Jul 15;25(14):1765-70 [10888943.001]
  • [Cites] BJU Int. 2000 Jun;85(9):1134-42 [10848710.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3058-64 [10850457.001]
  • [Cites] Endocrinology. 2000 Jun;141(6):2257-65 [10830316.001]
  • [Cites] Endocrinology. 2000 Jun;141(6):2254-6 [10830315.001]
  • [Cites] Endocrinology. 2000 Jun;141(6):2062-7 [10830291.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Mar;278(3):L545-51 [10710527.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1627-33 [10770208.001]
  • [Cites] Life Sci. 2000;66(2):91-103 [10666005.001]
  • [Cites] Prostate. 2000 Feb 15;42(3):203-10 [10639191.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):593-605 [16728585.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3024-33 [16540651.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 14;342(3):851-8 [16499871.001]
  • [Cites] Int J Oncol. 2006 Mar;28(3):723-30 [16465378.001]
  • [Cites] Oncogene. 2005 Nov 10;24(49):7310-9 [16158061.001]
  • [Cites] Exp Mol Med. 2005 Oct 31;37(5):391-8 [16264263.001]
  • [Cites] Endocrinology. 2005 Oct;146(10):4445-55 [15994346.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):407-20 [15886048.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1270-3 [15894684.001]
  • [Cites] J Clin Pathol. 2005 Apr;58(4):361-6 [15790698.001]
  • [Cites] BJU Int. 2005 May;95(7):987-91 [15839919.001]
  • [Cites] Eur Urol. 2005 May;47(5):695-702 [15826765.001]
  • [Cites] Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Mar;36(2):187-9 [15807262.001]
  • [Cites] Mol Cancer. 2005 Feb 2;4(1):7 [15686601.001]
  • [Cites] Breast Dis. 2003;17:49-59 [15687677.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):341-5 [15643522.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8620-9 [15574769.001]
  • [Cites] JAMA. 1965 Jun 28;192:1141-5 [14301034.001]
  • [Cites] Oncology. 1999 Nov;57(4):330-40 [10575321.001]
  • [Cites] J Natl Cancer Inst. 1999 Nov 17;91(22):1965-7 [10564682.001]
  • [Cites] Mol Cell Endocrinol. 1999 Sep 10;155(1-2):9-18 [10580834.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1758-64 [10528027.001]
  • [Cites] Endocrinology. 1998 Feb;139(2):807-10 [9449659.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4228-32 [10485462.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2B):1397-9 [10365112.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3098-103 [10077643.001]
  • [Cites] Endocrinology. 1999 May;140(5):2372-81 [10218991.001]
  • [Cites] J Endocrinol. 1998 Nov;159(2):227-32 [9795362.001]
  • [Cites] Endocrinology. 1998 Aug;139(8):3456-64 [9681496.001]
  • [Cites] Genomics. 1998 May 1;49(3):401-10 [9615225.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16836-42 [9642243.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1713-20 [9589681.001]
  • [Cites] Endocrinology. 1998 May;139(5):2356-62 [9564845.001]
  • [Cites] J Urol. 1998 Apr;159(4):1379-83 [9507888.001]
  • [Cites] Endocrinology. 1997 Oct;138(10):4240-7 [9322936.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20572-6 [9252371.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2308-13 [9215312.001]
  • [Cites] Endocrinology. 1997 Apr;138(4):1683-90 [9075731.001]
  • [Cites] Exp Cell Res. 1997 Feb 25;231(1):149-62 [9056422.001]
  • [Cites] J Cell Biochem. 1997 Jul 1;66(1):77-86 [9215530.001]
  • [Cites] Am J Physiol. 1996 Dec;271(6 Pt 1):L1014-22 [8997273.001]
  • [Cites] Endocrinol Metab Clin North Am. 1996 Sep;25(3):591-614 [8879988.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3774-82 [8855837.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4003-9 [15217931.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3988-95 [15217929.001]
  • [Cites] J Mol Endocrinol. 2004 Jun;32(3):859-68 [15171717.001]
  • [Cites] Gut. 2004 Jun;53(6):814-20 [15138207.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1600-3 [14996716.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):977-84 [14871828.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):675-84 [14710346.001]
  • [Cites] Prostate. 2004 Jan 1;58(1):41-9 [14673951.001]
  • [Cites] Cancer Causes Control. 2003 Oct;14(8):721-6 [14674736.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13970-5 [14617774.001]
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):773-9 [14696106.001]
  • [Cites] Endocrinology. 2003 Oct;144(10):4562-74 [12959972.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4315-21 [12907597.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3575-84 [12839944.001]
  • [Cites] Cancer Causes Control. 2003 Apr;14(3):285-92 [12814208.001]
  • [Cites] Endocrinology. 2003 Jul;144(7):2807-15 [12810534.001]
  • [Cites] Endocrinology. 2003 Jun;144(6):2417-24 [12746303.001]
  • [Cites] Endocrinology. 2003 Jun;144(6):2319-24 [12746292.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):14-9 [12672024.001]
  • [Cites] Growth Horm IGF Res. 2003 Feb;13(1):44-53 [12550081.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1566-73 [12496045.001]
  • [Cites] Practitioner. 1979 Feb;222(1328):211-7 [86186.001]
  • [Cites] Cancer Res. 1979 Jun;39(6 Pt 1):1973-9 [445396.001]
  • [Cites] CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40 [4625049.001]
  • [Cites] Proc Rudolf Virchow Med Soc City N Y. 1964;23:151-64 [5220432.001]
  • [Cites] Eur J Endocrinol. 2004 Aug;151 Suppl 1:S17-22 [15339239.001]
  • [Cites] Growth Horm IGF Res. 2004 Aug;14(4):277-86 [15231296.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2267-73 [17597108.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Sep;7(6):591-604 [17896924.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1857-61 [17546599.001]
  • [Cites] BMC Cancer. 2007;7:136 [17651480.001]
  • [Cites] J Cell Physiol. 2007 Oct;213(1):261-8 [17492783.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1121-7 [17548673.001]
  • [Cites] Oncogene. 2007 Apr 5;26(16):2308-17 [17016438.001]
  • [Cites] Endocr Rev. 2007 Feb;28(1):20-47 [16931767.001]
  • [Cites] J Mol Biol. 2006 Dec 8;364(4):690-704 [17020769.001]
  • [Cites] World J Gastroenterol. 2006 Oct 21;12(39):6285-9 [17072950.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 May;66(5):405-17 [17483698.001]
  • [Cites] Growth Horm IGF Res. 2006 Aug;16(4):224-39 [16893667.001]
  • (PMID = 19956425.001).
  • [ISSN] 1943-8141
  • [Journal-full-title] American journal of translational research
  • [ISO-abbreviation] Am J Transl Res
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016472
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2776314
  • [Keywords] NOTNLM ; Insulin-like growth factor, IGF / androgen insensitivity, AI / androgen sensitive, AS / neoplasm, bone, metastasis / prostate cancer, PCa
  •  go-up   go-down


72. Tibaldi C, Vasile E, Bernardini I, Orlandini C, Andreuccetti M, Falcone A: Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model. J Cancer Res Clin Oncol; 2008 Oct;134(10):1143-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model.
  • PURPOSE: We aimed to investigate the prognostic significance of several baseline variables in stage IIIB-IV non-small cell lung cancer to create a model based on independent prognostic factors.
  • Performance status of 2, squamous histology, number of metastatic sites >2, presence of bone, brain, liver and contralateral lung metastases and elevated leukocyte count in peripheral blood were all statistically significant prognostic factors in univariate analyses whereas the other tested variables (sex, stage, age, presence of adrenal gland and skin metastases) were not.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347812.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


73. Morio A, Ninomiya H, Sunada K, Tomioka K, Nakahara K: [A case of advanced non-small-cell lung cancer successfully treated with S-1 plus CBDCA after multiple chemotherapy]. Gan To Kagaku Ryoho; 2009 Sep;36(9):1533-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced non-small-cell lung cancer successfully treated with S-1 plus CBDCA after multiple chemotherapy].
  • He was diagnosed as left lung adenocarcinoma (c-T2N0M1, stage IV).
  • After the brain tumor extraction, CDDP (80 mg/m2) + GEM (1,000 mg/m2) were administered as first-line treatment, and the tumor response was PR (33.3% reduction rate), impaired liver function served to interrupt this regimen.
  • Other chemotherapy was then conducted in the order of GEM (1,000 mg/m2) + VNR (25 mg/m2), and CBDCA (AUC=5) + DOC(60 mg/m2), and the tumor response was NC.
  • After 3 courses of the treatment, the serum CEA level normalized, a chest CT detected the left lung tumor size reduction (66.7% reduction rate), and an abdominal CT detected disappearance of the left adrenal gland tumor.
  • Histopathological examination of the lung tumor showed viable adenocarcinoma cells.
  • This case suggests that S-1+CBDCA may be an effective treatment in patients with advanced non-small-cell lung cancer even after multiple chemotherapy.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755827.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; BG3F62OND5 / Carboplatin
  •  go-up   go-down


74. Aspinall SR, Imisairi AH, Bliss RD, Scott-Coombes D, Harrison BJ, Lennard TW: How is adrenocortical cancer being managed in the UK? Ann R Coll Surg Engl; 2009 Sep;91(6):489-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How is adrenocortical cancer being managed in the UK?
  • CONCLUSIONS: The size of tumour, stage and mode of presentation, age and overall survival of patients in this study are comparable to published series of adrenocortical carcinomas from major endocrine surgical centres world-wide.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use
  • [MeSH-minor] Adrenalectomy / methods. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Cytotoxins / therapeutic use. Great Britain. Humans. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis

  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2001 Jan;57(1):176-82 [11164177.001]
  • [Cites] Arch Pathol (Chic). 1949 Nov;48(5):387-94 [18143915.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1113-21 [11571723.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] ANZ J Surg. 2003 Sep;73(9):727-38 [12956790.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):789-92 [15191348.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):809-17 [15191351.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Jan;20(1):47-53 [6537915.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Surgery. 1992 Dec;112(6):972-9; discussion 979-80 [1455322.001]
  • [Cites] J Pharm Sci. 1995 Feb;84(2):134-8 [7738789.001]
  • [Cites] Radiology. 1995 Nov;197(2):411-8 [7480685.001]
  • [Cites] Surgery. 1996 Feb;119(2):161-70 [8571201.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jul;171(1):201-4 [9648789.001]
  • [Cites] Arch Surg. 1999 Feb;134(2):181-5 [10025460.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):718-26 [15581542.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4501-4 [16895957.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2415-8 [17554125.001]
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • (PMID = 19558758.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Cytotoxins; 78E4J5IB5J / Mitotane
  • [Other-IDs] NLM/ PMC2966201
  •  go-up   go-down


75. Bauditz J, Quinkler M, Wermke W: Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer--a case report and review of the literature. Exp Clin Endocrinol Diabetes; 2009 Jul;117(7):316-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer--a case report and review of the literature.
  • MATERIALS AND METHODS: We reviewed the literature, and report the case of a patient with stage 4 ACC who received intraoperative and percutaneous RFA of two liver metastasis according to a standard ablation protocol.
  • RESULTS: Post-interventional imaging in our patient demonstrated that after both interventions, a stellar-like structure of vital tumor tissue had remained within the coagulation necrosis.
  • This was the starting point of a fast and progressive tumor recurrence.
  • We suspect heat-sink effects of blood vessels in the highly vascularized metastasis to cause the tumor recurrence.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Carcinoma / pathology. Catheter Ablation. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19053031.001).
  • [ISSN] 1439-3646
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 23
  •  go-up   go-down


76. Kasperlik-Zaluska AA, Zgliczynski W, Slapa RZ, Cichocki A: Retroperitoneal hemorrhage from adrenocortical carcinoma as a poor prognostic factor. Int J Biomed Sci; 2008 Mar;4(1):78-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In most patients, adrenocortical carcinoma is diagnosed at an advanced stage of the disease.
  • A sudden retroperitoneal hemorrhage may sometimes be the first symptom of the adrenal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23675071.001).
  • [ISSN] 1550-9702
  • [Journal-full-title] International journal of biomedical science : IJBS
  • [ISO-abbreviation] Int J Biomed Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3614665
  • [Keywords] NOTNLM ; adrenal cancer / retroperitoneal hemorrhage / steroids
  •  go-up   go-down


77. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X, Bertherat J: Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab; 2006 Jul;91(7):2650-5
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.
  • Mean age at diagnosis was 44 +/- 16 yr (range, 11-88 yr).
  • We found that 154 patients (76%) had hypersecreting tumors [mostly cortisol and androgens (47%), cortisol alone (27%), or androgens alone (6%)] and 43 patients (21%) had metastases at diagnosis.
  • Multivariate analysis identified the following independent prognostic factors associated with shorter survival: older age at diagnosis [hazard ratio (HR), 1.03; P < 0.0001], initial MacFarlane extension stages 3 (HR, 4.42; P = 0.005) and 4 (HR, 7.93; P < 0.0001), and cortisol hypersecretion (HR, 3.90; P < 0.0001).
  • CONCLUSION: This study highlights the better prognosis of ACC diagnosed at a noninvasive local stage, the particularly poor prognosis of patients with cortisol-secreting tumors, and the beneficial effect of o,p'DDD therapy in this subgroup of patients.
  • [MeSH-major] Adrenal Cortex Neoplasms / secretion. Hydrocortisone / secretion
  • [MeSH-minor] Adult. Analysis of Variance. Androgens / secretion. Antineoplastic Agents, Hormonal / therapeutic use. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Mitotane / therapeutic use. Neoplasm Staging. Prognosis. Survival Rate

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670169.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


78. Haase M, Schott M, Bornstein SR, Malendowicz LK, Scherbaum WA, Willenberg HS: CITED2 is expressed in human adrenocortical cells and regulated by basic fibroblast growth factor. J Endocrinol; 2007 Feb;192(2):459-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CITED2 gene deletion in mice leads to adrenal agenesis.
  • Therefore, we analyzed CITED2, a CBP/p300 interacting transactivator with transforming activity, in the human adrenal gland.
  • In this study, we examined CITED2 expression in human embryonic and adult adrenal glands as well as adrenocortical carcinomas.
  • We found CITED2 expression in the adult adrenal cortex as well in adrenocortical carcinomas.
  • At an early stage of human adrenal organogenesis CITED2 could be located to the definitive zone of the developing adrenal gland using immunohistochemistry.
  • CITED2 is expressed in embryonic and adult human adrenal glands as well as in adrenocortical cancer.
  • This suggests a novel role for CITED2 in human adrenal growth and possibly in adrenal tumorigenesis.
  • [MeSH-major] Adrenal Cortex / metabolism. DNA-Binding Proteins / analysis. Fibroblast Growth Factor 2 / pharmacology. Gene Expression Regulation. Repressor Proteins / analysis. Trans-Activators / analysis
  • [MeSH-minor] Adrenocortical Carcinoma. Adrenocorticotropic Hormone / metabolism. Adrenocorticotropic Hormone / pharmacology. Adult. Cell Line, Tumor. Cells, Cultured. Colforsin / pharmacology. Dose-Response Relationship, Drug. Embryonic Development. Humans. Immunohistochemistry / methods. Microscopy, Fluorescence. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Transfection / methods

  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283246.001).
  • [ISSN] 0022-0795
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CITED2 protein, human; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Trans-Activators; 103107-01-3 / Fibroblast Growth Factor 2; 1F7A44V6OU / Colforsin; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


79. Lacroix A: Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab; 2010 Nov;95(11):4812-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adrenocortical cancer (ACC) is a rare and often aggressive malignancy that requires multidisciplinary expertise for optimal management.
  • Thorough imaging and endocrine evaluations can identify the majority of ACCs amongst adrenal tumors; however, some smaller ACCs are better identified using fluorodeoxyglucose-positron emission tomography/computed tomography scan.
  • Complete resection by an expert surgeon is the only potentially curative treatment for ACC, and tumor spillage should be avoided.
  • Histopathology is important for diagnosis, but immunohistochemistry markers and gene profiling of the resected tumor may become superior to current staging systems to stratify prognosis.
  • Despite complete resection in stage I-III tumors, approximately 40% of patients develop metastasis within 2 yr.
  • Careful replacement of glucocorticoid and mineralocorticoid deficiency after surgery or mitotane therapy is important; steroid excess from remaining tumor burden should also be controlled to avoid its morbidities.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21051577.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A: Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg; 2006 May;30(5):872-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adrenocortical carcinoma (ACC), a rare and aggressive malignancy, accounts for up to 14% of adrenal incidentalomas.
  • The only chance of cure for ACC is diagnosis at an early stage; therefore, a main indication for adrenalectomy in patients with adrenal incidentaloma has been the potential risk of ACC.
  • Recent studies suggest that this has led to earlier stage of ACC at diagnosis, more curative operations, and better survival.
  • METHODS: We analyzed data on ACC from The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database.
  • The average tumor size was 12 cm (range: 2-36 cm), and only 4.2% were < or = 6 cm.
  • Most (88%) patients had surgical resection of their tumor, and external beam radiotherapy was used in only 12% of patients.
  • Between the time quartiles compared (as well as annually), there was no significant difference at presentation in age at diagnosis, sex, race/ethnicity, tumor size, tumor grade, the frequency of distant metastasis, and overall TNM stage.
  • Low tumor grade, lower stage of ACC, later time quartile, and surgical resection were associated with a lower cause-specific mortality by univariate analysis (P < or = 0.002) and by multivariate analysis (P < or = 0.031).
  • CONCLUSIONS: Although adrenal incidentalomas have become a common indication for adrenalectomy, this has not resulted in patients with ACC being diagnosed earlier or treated at a lower stage of disease at the national level.
  • The most important predictors of survival in these patients are tumor grade, tumor stage, and surgical resection.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy. Adrenocortical Carcinoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Female. Humans. Infant. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. SEER Program. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680602.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Chung SD, Wang SM, Lai MK, Huang CY, Liao CH, Huang KH, Pu YS, Chueh SC, Yu HJ: Lymphovascular invasion predicts poor outcome of urothelial carcinoma of renal pelvis after nephroureterectomy. BJU Int; 2009 Apr;103(8):1047-51
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the significance of lymphovascular invasion (LVI) to predict cancer-specific survival (CSS) in patients with renal pelvic urothelial carcinoma (UC).
  • Inclusion criteria included nonmetastatic renal pelvic UC with no previous history of bladder cancer, concomitant ureteric lesion, or neoadjuvant chemotherapy.
  • Age, gender, adrenalectomized or not, pathological T stage, grade, and LVI were examined by univariate and multivariate analyses to determine which were independent risk factors.
  • At follow-up, eight cancer-related deaths (10.5%) were censored, and 66 patients (85.9%) were alive and disease-free.
  • CONCLUSIONS: Adrenal metastases from primary renal pelvic UCs were rare.
  • LVI appears to be a better prognostic factor for predicting poor outcome of renal pelvic UC than pT stage or tumour grade when using the current tumour-nodes-metastases staging system.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Kidney Neoplasms / surgery. Nephrectomy / methods
  • [MeSH-minor] Adrenalectomy / mortality. Adult. Aged. Aged, 80 and over. Epidemiologic Methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] BJU Int. 2009 Apr;103(8):1143 [19338572.001]
  • (PMID = 19076143.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Nevo I, Sagi-Assif O, Edry Botzer L, Amar D, Maman S, Kariv N, Leider-Trejo LE, Savelyeva L, Schwab M, Yron I, Witz IP: Generation and characterization of novel local and metastatic human neuroblastoma variants. Neoplasia; 2008 Aug;10(8):816-27
Hazardous Substances Data Bank. DESFERRIOXAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroblastoma (NB) is the most commonly occurring solid tumor in children.
  • The disease usually arises in the adrenal medulla, and it is characterized by a remarkable heterogeneity in its progression.
  • Most NB patients with an advanced disease have massive bone marrow infiltration at diagnosis.
  • Lung metastasis represents a widely disseminated stage and is typically considered to be a terminal event.
  • Currently, models consisting of metastatic and nonmetastatic cell variants of the same genetic background exist for several types of cancer; however, none exists for NB.
  • SH-SY5Y and MHH-NB-11 NB cells were inoculated orthotopically into the adrenal glands of athymic nude mice.
  • Neuroblastoma cells metastasizing to the lungs were isolated from mice bearing adrenal tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Disease Models, Animal. Lung Neoplasms / secondary. Neoplasms, Experimental / secondary. Neuroblastoma / secondary
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Deferoxamine / pharmacology. Doxorubicin / therapeutic use. Drug Screening Assays, Antitumor. Flow Cytometry. Humans. Immunophenotyping. Karyotyping. Male. Matrix Metalloproteinase 2 / secretion. Matrix Metalloproteinase 9 / secretion. Mice. Mice, Inbred BALB C. Mice, Nude. Survival Rate. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2006 Oct;6(10):764-75 [16990854.001]
  • [Cites] Immunobiology. 2006;211(5):377-89 [16716807.001]
  • [Cites] Cancer Metastasis Rev. 2006 Dec;25(4):645-57 [17160711.001]
  • [Cites] Clin Exp Metastasis. 2003;20(3):237-50 [12741682.001]
  • [Cites] Clin Exp Metastasis. 2007;24(1):57-66 [17357815.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):319-31 [17458507.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):9-13 [18172289.001]
  • [Cites] Neoplasia. 1999 Apr;1(1):50-62 [10935470.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jul;59(1):15-26 [16716598.001]
  • [Cites] Bull Cancer. 2006 Aug;93(8):E73-80 [16935775.001]
  • [Cites] Life Sci. 2001 Jan 26;68(10):1161-8 [11228100.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):755-9 [11222220.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):313-8 [11291063.001]
  • [Cites] J Immunol. 2001 Oct 15;167(8):4747-57 [11591806.001]
  • [Cites] In Vivo. 2002 Mar-Apr;16(2):77-85 [12073775.001]
  • [Cites] Cytometry. 2002 Dec 15;50(6):298-304 [12497591.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):203-16 [12612655.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5532-9 [14654533.001]
  • [Cites] Immunol Lett. 2004 Mar 29;92(1-2):163-9 [15081541.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Aug;130(8):460-8 [15146329.001]
  • [Cites] Cancer Res. 1973 Nov;33(11):2643-52 [4748425.001]
  • [Cites] Cancer Res. 1978 Nov;38(11 Pt 1):3751-7 [29704.001]
  • [Cites] J Immunol. 1979 Jul;123(1):342-9 [87477.001]
  • [Cites] J Immunol. 1981 Jan;126(1):317-21 [6935293.001]
  • [Cites] Cancer Res. 1981 Aug;41(8):3058-64 [7248962.001]
  • [Cites] AJR Am J Roentgenol. 1982 Jan;138(1):75-8 [6976716.001]
  • [Cites] Cancer Treat Rep. 1986 Aug;70(8):959-65 [3731152.001]
  • [Cites] Cancer Res. 1987 Mar 1;47(5):1383-9 [3028608.001]
  • [Cites] Cancer Res. 1987 Apr 1;47(7):1749-50 [3815370.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1943-8 [3349467.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):7189-92 [3191493.001]
  • [Cites] Anticancer Res. 1988 Nov-Dec;8(6):1329-33 [3218965.001]
  • [Cites] Cancer Res. 1989 May 1;49(9):2383-9 [2539901.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3610-5 [8260699.001]
  • [Cites] Cell Growth Differ. 1995 Apr;6(4):449-56 [7794812.001]
  • [Cites] Eur J Cancer. 1995;31A(4):612-5 [7576980.001]
  • [Cites] Eur J Cancer. 1995;31A(4):616-21 [7576981.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2347-50 [8572650.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):379-85 [8707412.001]
  • [Cites] Cancer. 1997 May 1;79(9):1757-66 [9128993.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):429-32 [9143388.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2209-16 [9605768.001]
  • [Cites] Oral Oncol. 1998 Jul;34(4):253-6 [9813718.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5396-405 [9850071.001]
  • [Cites] Cytokine. 2005 Feb 7;29(3):105-17 [15613278.001]
  • [Cites] Clin Exp Metastasis. 2004;21(6):563-70 [15679054.001]
  • [Cites] World J Surg. 2005 Mar;29(3):317-24 [15706435.001]
  • [Cites] Biochim Biophys Acta. 2005 May 25;1755(1):37-69 [15907591.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4117-24 [16618732.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):9-34 [16680569.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • (PMID = 18683320.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 80168379AG / Doxorubicin; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; J06Y7MXW4D / Deferoxamine
  • [Other-IDs] NLM/ PMC2504768
  •  go-up   go-down


83. Kim YS, Kim N, Kim SY, Cho KS, Park MJ, Choi SH, Lim SH, Yim JY, Cho KR, Kim CH, Kim DH, Kim SS, Kim JH, Choi BI, Jung HC, Song IS, Shin CS, Cho SH, Oh BH: Extracolonic findings in an asymptomatic screening population undergoing intravenous contrast-enhanced computed tomography colonography. J Gastroenterol Hepatol; 2008 Jul;23(7 Pt 2):e49-57
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • New extracolonic cancer was detected in 0.5% (12/2230), and the majority of them (83.3%) were not metastasized.
  • Computed tomography colonography missed eight potentially important extracolonic findings in eight subjects (0.4%, 8/2230): 0.8-cm early-stage prostatic cancer, six adrenal mass and one intraductal papillary mucinous tumor.
  • CONCLUSION: Intravenous contrast-enhanced CTC could safely detect asymptomatic early-stage extracolonic malignant diseases without an unreasonable number of additional work-ups, thus reducing their morbidity or mortality.
  • [MeSH-minor] Adrenal Glands / radiography. Aged. Aged, 80 and over. Biliary Tract / radiography. Blood Vessels / pathology. Cost-Benefit Analysis. Early Diagnosis. Esophagus / radiography. Female. Humans. Injections, Intravenous. Kidney / radiography. Liver / radiography. Lung / radiography. Male. Medical Records. Middle Aged. Pancreas / radiography. Predictive Value of Tests. Prospective Studies. Stomach / radiography. Time Factors. Urogenital System / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645481.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


84. Groussin L, Bonardel G, Silvéra S, Tissier F, Coste J, Abiven G, Libé R, Bienvenu M, Alberini JL, Salenave S, Bouchard P, Bertherat J, Dousset B, Legmann P, Richard B, Foehrenbach H, Bertagna X, Tenenbaum F: 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab; 2009 May;94(5):1713-22
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients.
  • CONTEXT: Most adrenal incidentalomas are nonfunctioning adrenocortical adenomas (ACAs).
  • Adrenocortical carcinomas (ACCs) are rare but should be recognized at an early stage.
  • OBJECTIVE: The objective of the study was to evaluate the usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) to predict malignancy in patients without a previous history of cancer.
  • Using a cutoff value above 1.45 for adrenal to liver maxSUV ratio, the sensitivity and specificity to distinguish ACAs from ACCs were, respectively, 1.00 (95% confidence interval 0.85-1.00) and 0.88 (95% confidence interval 0.75-0.96).
  • An adrenal to liver maxSUV ratio less than 1.45 is highly predictive of a benign lesion.
  • [MeSH-major] Adrenal Cortex Neoplasms / radionuclide imaging. Adrenal Cortex Neoplasms / surgery. Fluorodeoxyglucose F18

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190108.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Hormones; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


85. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Frank I, Zincke H, Blute ML: Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol; 2005 Oct;174(4 Pt 1):1218-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Perinephric and renal sinus fat invasion are classified as pT3a renal cell carcinoma (RCC) according to the 2002 American Joint Committee on Cancer.
  • MATERIALS AND METHODS: Between 1970 and 2002, 205 patients without direct adrenal invasion underwent nephrectomy for pT3a clear cell RCC.
  • In addition, the risk of death persisted in multivariate analysis after adjusting for regional lymph nodes and distant metastases (RR 1.91, 95% CI 1.26-2.89, p=0.002) and after adjusting for the Mayo Clinic SSIGN (stage, size, grade and necrosis) score (RR 1.90, 95% CI 1.25-2.88, p=0.003).
  • [MeSH-minor] Adipose Tissue / pathology. Adrenal Glands / pathology. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Adv Anat Pathol. 2007 Mar;14(2):63-8 [17471114.001]
  • (PMID = 16145373.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Loria P, Carulli L, Bertolotti M, Lonardo A: Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol; 2009 Apr;6(4):236-47

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypothyroidism, for example, might lead to NASH, cirrhosis and potentially liver cancer via the development of hyperlipidemia and obesity.
  • In addition, adrenal failure is increasingly reported in patients with end stage liver disease and in patients who have received a liver transplant, which suggests a bidirectional relationship between liver and endocrine functions.
  • [MeSH-minor] Adrenal Insufficiency / complications. Female. Growth Hormone / deficiency. Humans. Male. Polycystic Ovary Syndrome / complications. Thyroid Gland / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347015.001).
  • [ISSN] 1759-5053
  • [Journal-full-title] Nature reviews. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Rev Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  • [Number-of-references] 125
  •  go-up   go-down


87. Fujino M, Shirato H, Onishi H, Kawamura H, Takayama K, Koto M, Onimaru R, Nagata Y, Hiraoka M: Characteristics of patients who developed radiation pneumonitis requiring steroid therapy after stereotactic irradiation for lung tumors. Cancer J; 2006 Jan-Feb;12(1):41-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To find possible risk factors for symptomatic radiation pneumonitis (RP) after stereotactic irradiation (STI) for peripheral non-small cell lung cancer (NSCLC), pre-treatment pulmonary function test and dose volume statistics in patients who developed RP requiring steroid intake were retrospectively compared with statistics of those who did not develop RP.
  • MATERIALS AND METHODS: From 1996 to 2002, 156 patients with Stage I NSCLC received STI at 5 hospitals in Japan.
  • RESULTS: There were no statistical differences in age, sex, tumor size, performance status, forced expiratory volume in 1 sec (FEV1.0%), or percent vital capacity (%VC) between patients medicated with steroids for RP and those who did not have RP and received no steroids.
  • CONCLUSIONS: Pre-treatment pulmonary function test (%VC, FEV1.0%), and dose volume statistics V20, total dose, BED, dose per fraction, peripheral dose) were not predictive of RP requiring steroid intake after STI for stage I NSCLC.
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Radiotherapy Dosage. Respiratory Function Tests. Retrospective Studies. Risk Factors. Stereotaxic Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer J. 2006 Jan-Feb;12(1):19-20 [16613657.001]
  • (PMID = 16613661.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


88. Mercadante S, Casuccio A, Mangione S: Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage; 2007 Feb;33(2):217-23
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review.
  • The use of symptomatic agents has greatly improved the medical treatment of advanced cancer patients with inoperable bowel obstruction.
  • A systematic review of studies of the most popular drugs used in the medical management of inoperable malignant bowel obstruction was performed to assess the effectiveness of these treatments and provide some lines of evidence.
  • Randomized trials that involved patients with a clinical diagnosis of intestinal obstruction due to advanced cancer treated with these drugs were reviewed.
  • The latter studies had samples more defined in terms of stage and inoperability, and had a shorter survival in comparison with studies of CSs (less than 61 days, most of them less than 20 days).
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Butylscopolammonium Bromide / therapeutic use. Humans. Muscarinic Antagonists / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17280927.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Gastrointestinal Agents; 0 / Muscarinic Antagonists; 2Z3E1OF81V / Butylscopolammonium Bromide; RWM8CCW8GP / Octreotide
  • [Number-of-references] 14
  •  go-up   go-down


89. Yang JY, Yang MQ, Luo Z, Ma Y, Li J, Deng Y, Huang X: A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions. BMC Genomics; 2008;9 Suppl 1:S23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The prognosis for many cancers could be improved dramatically if they could be detected while still at the microscopic disease stage.
  • It follows from a comprehensive statistical analysis that a number of antigens such as hTERT, PCNA and Ki-67 can be considered as cancer markers, while another set of antigens such as P27KIP1 and FHIT are possible markers for normal tissue.
  • Because more than one marker must be considered to obtain a classification of cancer or no cancer, and if cancer, to classify it as malignant, borderline, or benign, we must develop an intelligent decision system that can fullfill such an unmet medical need.
  • We provided statistical evidence that higher expression levels of hTERT, PCNA and Ki-67 etc. are associated with a higher risk that the tumors are malignant or borderline as opposed to benign.
  • While no significant difference was found between cell-arrest antigens such as P27KIP1 for malignant, borderline, and benign tumors, there was a significant difference between expression levels of such antigens in normal adrenal medulla samples and in adrenomedullary tumors.
  • This research has many potential applications; it might provide an alternative diagnostic tool and a better understanding of the mechanisms involved in malignant transformation as well as information that is useful for treatment planning and cancer prevention.
  • [MeSH-major] Adrenal Cortex Neoplasms / classification. Algorithms. Artificial Intelligence. Biomarkers, Tumor / metabolism. Cushing Syndrome / classification

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):376-81 [11875703.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2995-9 [12926152.001]
  • [Cites] Int J Mol Med. 2003 Oct;12(4):437-42 [12964015.001]
  • [Cites] Cancer Lett. 2003 Sep 25;199(2):131-8 [12969785.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5299-306 [14602765.001]
  • [Cites] Ultrastruct Pathol. 2003 Nov-Dec;27(6):417-22 [14660280.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2000-6 [15026336.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1472-7 [15042681.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2363-70 [15197197.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Aug;261(7):376-80 [14605812.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5745-52 [15313915.001]
  • [Cites] Eur J Cancer. 2004 Sep;40(14):2175-83 [15341994.001]
  • [Cites] Cell Oncol. 2004;26(1-2):13-20 [15371653.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1571-4 [15467769.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] J Pathol. 1992 Oct;168(2):161-2 [1460534.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):278-81 [7530983.001]
  • [Cites] Cell. 1996 Feb 23;84(4):587-97 [8598045.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Sep;32B(5):328-32 [8944836.001]
  • [Cites] Zentralbl Chir. 1997;122(6):430-7 [9334108.001]
  • [Cites] Arch Surg. 1997 Aug;132(8):914-9 [9267279.001]
  • [Cites] J Pediatr Surg. 1998 Apr;33(4):644-6 [9574770.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2533-6 [9635574.001]
  • [Cites] Trends Biochem Sci. 1998 Jul;23(7):236-8 [9697409.001]
  • [Cites] Br J Urol. 1998 Aug;82(2):199-205 [9722754.001]
  • [Cites] Anal Cell Pathol. 1998;16(4):185-92 [9762365.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4708-14 [9788626.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3615-20 [11891319.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(5):728-35 [11916557.001]
  • [Cites] Gynecol Oncol. 2002 Jun;85(3):404-14 [12051866.001]
  • [Cites] J Neurooncol. 2002 Apr;57(2):115-21 [12125971.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):455-7 [12543802.001]
  • [Cites] Oncogene. 2003 Jan 23;22(3):461-6 [12545168.001]
  • [Cites] Int J Mol Med. 2003 Apr;11(4):441-7 [12632095.001]
  • [Cites] Vet Pathol. 2003 Mar;40(2):136-42 [12637752.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):187-91 [12640096.001]
  • [Cites] Head Neck. 2003 Apr;25(4):280-8 [12658732.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Feb;129(2):84-8 [12669232.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1213-6 [12698186.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 May;15(5):515-23 [12702909.001]
  • [Cites] APMIS. 2003 Apr;111(4):451-7 [12780518.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3724-8 [12839965.001]
  • [Cites] Laryngorhinootologie. 2003 Jun;82(6):436-7 [12851852.001]
  • [Cites] Mol Pathol. 2003 Aug;56(4):226-31 [12890744.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):331-7 [12893195.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2837-43 [12926121.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5032-7 [9823304.001]
  • [Cites] Int J Antimicrob Agents. 1998 Aug;10(3):245-8 [9832286.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5478-83 [9850082.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):12-20 [9858527.001]
  • [Cites] Ann Intern Med. 1999 May 4;130(9):759-71 [10357696.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1618-24 [10334551.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8489-92 [10411902.001]
  • [Cites] Methods. 1999 Jul;18(3):401-6 [10455000.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2165-71 [15231689.001]
  • [Cites] J Cell Physiol. 2005 Feb;202(2):518-23 [15389587.001]
  • [Cites] Mol Cancer. 2004 Dec 1;3:33 [15574200.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R28-32 [15642167.001]
  • [Cites] Biol Cell. 2005 Mar;97(3):221-9 [15584900.001]
  • [Cites] Oncogene. 2005 Mar 3;24(10):1774-87 [15674352.001]
  • [Cites] Biochemistry (Mosc). 2005 Mar;70(3):275-91 [15823082.001]
  • [Cites] Arkh Patol. 2005 Mar-Apr;67(2):13-7 [15938112.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jul;24(3):228-34 [15968197.001]
  • [Cites] Br J Surg. 2005 Aug;92(8):1002-7 [15931661.001]
  • [Cites] J Mol Recognit. 2005 Sep-Oct;18(5):343-84 [16094605.001]
  • [Cites] Gynecol Oncol. 2002 Aug;86(2):144-9 [12144820.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3898-905 [12228211.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2890-3 [12231533.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):994-1002 [16153463.001]
  • [Cites] World J Gastroenterol. 2005 Sep 28;11(36):5735-8 [16237777.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 30;265(3):658-63 [10600477.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):18-21 [10646844.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):570-6 [10747315.001]
  • [Cites] BJU Int. 2000 Apr;85(6):759-66 [10759680.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2341-8 [10873085.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):966-78 [10888772.001]
  • [Cites] Scand J Gastroenterol. 2000 Jun;35(6):637-41 [10912665.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(3):267-72 [10949392.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Dec;123(6):779-83 [11112979.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):270-5 [11161387.001]
  • [Cites] J Cutan Pathol. 2001 Mar;28(3):120-6 [11168762.001]
  • [Cites] Bioinformatics. 2000 Dec;16(12):1062-72 [11159325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3346-51 [11248081.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3581-5 [11325823.001]
  • [Cites] Br J Cancer. 2001 Jul 20;85(2):247-54 [11461085.001]
  • [Cites] Eur J Endocrinol. 2001 Sep;145(3):335-41 [11517015.001]
  • [Cites] Mol Cell. 2001 Aug;8(2):407-15 [11545742.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8659-63 [11751381.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):514-9 [11839671.001]
  • (PMID = 18366613.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proliferating Cell Nuclear Antigen
  • [Other-IDs] NLM/ PMC2386065
  •  go-up   go-down


90. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G, Hammer G: Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res; 2009 Jan 15;15(2):668-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using Affymetrix Human Genome U133 Plus 2.0 oligonucleotide arrays, transcriptional profiles were generated for 10 normal adrenal cortices (NC), 22 adrenocortical adenomas (ACA), and 33 ACCs.
  • Cluster analysis of the ACCs revealed two subtypes that reflected tumor proliferation, as measured by mitotic counts and cell cycle genes.
  • Multivariate Cox modeling using stage, mitotic rate, and gene expression data as measured by the first principal component for ACC samples showed that gene expression data contains significant independent prognostic information (P < 0.017).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1039-45 [10514385.001]
  • [Cites] World J Surg. 2004 Sep;28(9):896-903 [15593464.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1819-29 [15613424.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):579-83 [15920519.001]
  • [Cites] Eur J Endocrinol. 2005 Oct;153(4):477-87 [16189167.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6646-56 [16007166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Surgery. 2005 Dec;138(6):1087-94 [16360395.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):587-98 [16556722.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1043-8 [16921376.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5079-90 [17075127.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Nov;2(11):632-41 [17082810.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5 [17099226.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):600-8 [17234769.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):1-12 [17237261.001]
  • [Cites] Endocr Rev. 2007 Feb;28(1):20-47 [16931767.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):13-28 [17395972.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):175-8 [17427106.001]
  • [Cites] APMIS. 2007 Apr;115(4):381-4 [17504308.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):345-54 [17525483.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):355-63 [17525484.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Oct;4(10):591-602 [17898809.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):425-31 [18281524.001]
  • [Cites] Endocr J. 2008 Mar;55(1):49-55 [18187873.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1442-9 [18198226.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):145-52 [10824999.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1231-8 [11583950.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1170-6 [11889182.001]
  • [Cites] Endocr Pathol. 2001 Winter;12(4):397-406 [11914473.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3467-74 [12107267.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6810-8 [14555994.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1985-95 [14578198.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):809-17 [15191351.001]
  • [Cites] Horm Metab Res. 2004 Jun;36(6):397-405 [15241731.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4219-23 [8797595.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Mol Endocrinol. 1999 Aug;23(1):23-32 [10425444.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3246-8 [15180930.001]
  • (PMID = 19147773.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA046592-209023; United States / NCI NIH HHS / CA / CA046592-219023; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / CA046592-199023; United States / NCI NIH HHS / CA / P30 CA046592-219023; United States / NCI NIH HHS / CA / P30 CA046592-199023; United States / NCI NIH HHS / CA / P30 CA046592-209023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin E
  • [Other-IDs] NLM/ NIHMS78831; NLM/ PMC2629378
  •  go-up   go-down


91. Zini L, Capitanio U, Jeldres C, Lughezzani G, Sun M, Shariat SF, Isbarn H, Arjane P, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI: External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. BJU Int; 2009 Dec;104(11):1661-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To develop nomograms predicting cancer-specific and all-cause mortality in patients managed with either surgery or no surgery for adrenocortical carcinoma (ACC).
  • The predictors comprised age, gender, race, stage and surgery status.
  • Nomograms based on Cox regression model-derived coefficients were used for predicting the cancer-specific and all-cause mortality, and were tested using area under the receiver operating characteristics (ROC) curve.
  • RESULTS: In cancer-specific analyses, the median survival of patients within the development cohort was 26 months, vs 71 months in the external validation cohort (P < 0.001).
  • Three variables (age, stage and surgical status) were included in the nomograms predicting cancer-specific and all-cause mortality.
  • In the external validation cohort, the nomograms achieved between 72 and 80% accuracy for prediction of cancer-specific or all-cause mortality at 1-5 years after either surgery or diagnosis of ACC for non-surgical patients.
  • [MeSH-major] Adrenal Cortex Neoplasms / mortality. Adrenocortical Carcinoma / mortality. Nomograms

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19493261.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


92. Nguyen CT, Campbell SC: Staging of renal cell carcinoma: past, present, and future. Clin Genitourin Cancer; 2006 Dec;5(3):190-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor stage, which describes the anatomic extent of disease, is a powerful determinant of prognosis and survival for patients with renal cell carcinoma (RCC).
  • Staging for RCC has evolved from the Robson classification into the TNM system, developed by the International Union Against Cancer and the American Joint Committee on Cancer.
  • Nevertheless, additional modifications have been proposed that would alter the subclassification of organ-confined disease, integrate various levels of venous involvement with other aspects of local tumor aggressiveness, and upgrade the classification of adrenal involvement.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Neoplasm Staging / trends
  • [MeSH-minor] Biomarkers, Tumor / analysis. Forecasting. History, 20th Century. History, 21st Century. Humans. Prognosis. Renal Veins / physiopathology. Venous Thrombosis / physiopathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239272.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 94
  •  go-up   go-down


93. Welch C, Chen Y, Stallings RL: MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene; 2007 Jul 26;26(34):5017-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells.
  • Neuroblastoma (NB) is one of the most common forms of cancer in children, accounting for 15% of pediatric cancer deaths.
  • The clinical course of these tumors is highly variable and is dependent on such factors as age at presentation, stage, ploidy and genomic abnormalities.
  • Hemizygous deletion of chromosome 1p occurs in approximately 30% of advanced stage tumors, is associated with a poor prognosis, and likely leads to the loss of one or more tumor suppressor genes.
  • We show here that microRNA (miRNA)-34a (1p36.23) is generally expressed at lower levels in unfavorable primary NB tumors and cell lines relative to normal adrenal tissue and that reintroduction of this miRNA into three different NB cell lines causes a dramatic reduction in cell proliferation through the induction of a caspase-dependent apoptotic pathway.
  • Thus, adding to the increasing role of miRNAs in cancer, miR-34a may act as a suppressor of NB tumorgenesis.
  • [MeSH-major] Apoptosis. Genes, Tumor Suppressor. MicroRNAs / physiology. Neuroblastoma / genetics
  • [MeSH-minor] Cell Line, Tumor. Child. Chromosome Deletion. Chromosomes, Human, Pair 1. E2F3 Transcription Factor / genetics. Gene Expression Regulation, Neoplastic. Humans

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17297439.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / E2F3 Transcription Factor; 0 / E2F3 protein, human; 0 / MIRN34 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


94. Müller-Horvat C, Radny P, Eigentler TK, Schäfer J, Pfannenberg C, Horger M, Khorchidi S, Nägele T, Garbe C, Claussen CD, Schlemmer HP: Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer; 2006 Feb;42(3):342-50
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma.
  • Patient management and treatment strategies for metastatic melanoma depend largely on the stage of metastatic disease.
  • A total of 43 patients (41 with completed wbCT and wbMRI examination) with known American Joint Committee on Cancer (AJCC) stage III-IV malignant melanoma were examined and 775 metastases were identified by both methods.
  • In kidneys, adrenal glands and lymph nodes, respectively, wbCT and wbMRI detected the same number of lesions.
  • In conclusion, wbMRI detected clearly more malignant melanoma metastases in most organ systems with the exception of lung metastases.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Melanoma / diagnosis. Skin Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Decision Making. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis / diagnosis. Neoplasm Staging / methods. Prognosis. Prospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364631.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Chuang KL, Liaw CC, Ueng SH, Liao SK, Pang ST, Chang YH, Chuang HC, Chuang CK: Mixed germ cell tumor metastatic to the skin: case report and literature review. World J Surg Oncol; 2010;8:21
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed germ cell tumor metastatic to the skin: case report and literature review.
  • BACKGROUND: Testicular cancer is the most common cancer for males aged 15 to approximately 35 years old.
  • Other metastatic sites include the lung, liver, brain, adrenal glands, gastrointestinal tract and spleen.
  • CASE PRESENTATION: A 19-year old male was diagnosed testicular mixed germ cell tumor with initial presentation of cutaneous metastasis at scalp and upper abdomen.
  • CONCLUSIONS: For advanced stage testicular cancer, cisplatin-based chemotherapy is still effective to achieve partial response.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cutis. 2001 Feb;67(2):117-20 [11236220.001]
  • [Cites] Clin Exp Dermatol. 2002 Jan;27(1):64-5 [11952675.001]
  • [Cites] Int J Urol. 2003 Feb;10(2):103-4 [12588608.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 May;18(3):386-7 [15096171.001]
  • [Cites] Urology. 2004 Jun;63(6):1021-6 [15183939.001]
  • [Cites] J Cutan Pathol. 2004 Jul;31(6):419-30 [15186430.001]
  • [Cites] J Cutan Pathol. 2010 Apr;37(4):486-90 [19469863.001]
  • [Cites] Vopr Onkol. 1981;27(4):70-3 [7195101.001]
  • [Cites] Cancer. 1982 Aug 1;50(3):548-51 [6284333.001]
  • [Cites] Hinyokika Kiyo. 1983 Feb;29(2):155-68 [6687145.001]
  • [Cites] Cutis. 1987 Feb;39(2):119-21 [3829718.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Urology. 2006 Apr;67(4):846.e15-7 [16600346.001]
  • [Cites] J Urol. 1976 Nov;116(5):593-7 [988197.001]
  • (PMID = 20331874.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2851696
  •  go-up   go-down


96. Dong W, Willett KL: Local expression of CYP19A1 and CYP19A2 in developing and adult killifish (Fundulus heteroclitus). Gen Comp Endocrinol; 2008 Jan 15;155(2):307-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 90 dpf (day post-fertilization) fish and adult fish, CYP19A1 was expressed in the ooplasm of early stage I oocytes (primary growth stage).
  • Expression of CYP19A1 was localized in the follicle cell layer of late stage I (previtellogenic stage) and stage II (vitellogenic stage) follicles, but by stage III (early maturational follicles) CYP19A1 expression was localized in the vitelline envelope.
  • Overall, CYP19A1 oocyte membrane expression gradually declined from highest expression at late stage I to nondetectable levels by stage IV.
  • In addition to the brain, there was strong CYP19A2 signal in adrenal/kidney cells in 6-14 dpf embryos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Sci. 2000 Oct;57(2):229-39 [11006353.001]
  • [Cites] J Comp Neurol. 2007 Mar 1;501(1):150-67 [17206614.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):740-50 [11159846.001]
  • [Cites] Environ Health Perspect. 2001 Mar;109(3):257-64 [11333187.001]
  • [Cites] Environ Toxicol Chem. 2001 May;20(5):985-95 [11337888.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 2001 Jun;129(2-3):261-8 [11399458.001]
  • [Cites] Mol Reprod Dev. 2001 Aug;59(4):359-70 [11468772.001]
  • [Cites] J Exp Zool. 2001 Sep 15;290(5):475-83 [11555854.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 2;288(3):503-8 [11676471.001]
  • [Cites] J Neurosci. 2001 Nov 15;21(22):8943-55 [11698605.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Nov;78(5):427-39 [11738553.001]
  • [Cites] Annu Rev Physiol. 2002;64:93-127 [11826265.001]
  • [Cites] Horm Res. 2002;57(5-6):145-52 [12053085.001]
  • [Cites] Toxicol Sci. 2002 Sep;69(1):191-201 [12215674.001]
  • [Cites] J Comp Neurol. 2003 Jul 21;462(2):180-93 [12794742.001]
  • [Cites] Gen Comp Endocrinol. 2003 Jun 15;132(2):223-30 [12812769.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):381-6 [14623534.001]
  • [Cites] Zoolog Sci. 2004 Apr;21(4):417-25 [15118229.001]
  • [Cites] Mol Cell Endocrinol. 2004 Apr 30;219(1-2):83-94 [15149730.001]
  • [Cites] Gen Comp Endocrinol. 2004 Oct;139(1):72-84 [15474538.001]
  • [Cites] Gen Comp Endocrinol. 1968 Feb;10(1):126-37 [4384686.001]
  • [Cites] J Exp Zool. 1983 Jun;226(3):441-57 [6886667.001]
  • [Cites] Dev Biol. 1985 Aug;110(2):492-8 [4018410.001]
  • [Cites] Gen Comp Endocrinol. 1989 Jan;73(1):147-56 [2920896.001]
  • [Cites] Gen Comp Endocrinol. 1989 Nov;76(2):230-40 [2591717.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5978-86 [2168287.001]
  • [Cites] J Biochem. 1995 Apr;117(4):719-25 [7592531.001]
  • [Cites] Biol Reprod. 1996 Apr;54(4):809-18 [8924500.001]
  • [Cites] Biol Reprod. 1996 Feb;54(2):497-505 [8788204.001]
  • [Cites] Gen Comp Endocrinol. 1996 Jul;103(1):24-35 [8812325.001]
  • [Cites] Gen Comp Endocrinol. 1997 May;106(2):155-68 [9169111.001]
  • [Cites] Biol Reprod. 1998 Jul;59(1):53-61 [9674993.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Sep;92(1-2):39-50 [15544929.001]
  • [Cites] Gen Comp Endocrinol. 2005 Jan 1;140(1):74-83 [15596073.001]
  • [Cites] BMC Genomics. 2004;5(1):96 [15610557.001]
  • [Cites] J Comp Neurol. 2005 Feb 28;483(1):91-113 [15672394.001]
  • [Cites] Aquat Toxicol. 2005 Mar 4;71(4):357-69 [15710483.001]
  • [Cites] Aquat Toxicol. 2005 Mar 4;71(4):371-89 [15710484.001]
  • [Cites] J Comp Neurol. 2005 May 16;485(4):304-20 [15803511.001]
  • [Cites] Gen Comp Endocrinol. 2005 May 15;142(1-2):60-6 [15862549.001]
  • [Cites] Gene Expr Patterns. 2005 Jun;5(5):655-67 [15939378.001]
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2005 May;141(1):54-9 [15916910.001]
  • [Cites] Gen Comp Endocrinol. 2005 Aug;143(1):21-32 [15993101.001]
  • [Cites] Aquat Toxicol. 2005 Jul 30;73(4):327-41 [15916819.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Jun;96(1):67-77 [15876529.001]
  • [Cites] Gen Comp Endocrinol. 2005 Dec;144(3):224-31 [16102755.001]
  • [Cites] Aquat Toxicol. 2006 May 10;77(3):267-78 [16458981.001]
  • [Cites] Gen Comp Endocrinol. 2006 Jun;147(2):108-17 [16458310.001]
  • [Cites] Toxicol Sci. 2006 Aug;92(2):526-36 [16687390.001]
  • [Cites] Toxicol Sci. 2006 Oct;93(2):331-40 [16873418.001]
  • [Cites] Toxicol Sci. 2006 Nov;94(1):3-21 [16807284.001]
  • [Cites] Gen Comp Endocrinol. 2006 Nov;149(2):205-16 [16872606.001]
  • [Cites] Mol Cell Endocrinol. 2007 Jan 15;263(1-2):65-78 [17079073.001]
  • [Cites] Gen Comp Endocrinol. 2007 Jan 1;150(1):174-88 [16962596.001]
  • [Cites] Brain Res. 2006 Dec 18;1126(1):91-101 [17045250.001]
  • [Cites] Environ Sci Technol. 2007 Jan 1;41(1):321-30 [17265966.001]
  • [Cites] Biol Reprod. 2000 Dec;63(6):1676-82 [11090435.001]
  • (PMID = 17582409.001).
  • [ISSN] 0016-6480
  • [Journal-full-title] General and comparative endocrinology
  • [ISO-abbreviation] Gen. Comp. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016476; United States / NCRR NIH HHS / RR / RR016476; United States / NIEHS NIH HHS / ES / R01 ES012710; United States / NIEHS NIH HHS / ES / ES012710-04; United States / NIEHS NIH HHS / ES / R01ES012710; United States / NIEHS NIH HHS / ES / R01 ES012710-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fish Proteins; 0 / Isoenzymes; EC 1.14.14.1 / Aromatase
  • [Other-IDs] NLM/ NIHMS38783; NLM/ PMC2254941
  •  go-up   go-down


97. Libè R, Groussin L, Tissier F, Elie C, René-Corail F, Fratticci A, Jullian E, Beck-Peccoz P, Bertagna X, Gicquel C, Bertherat J: Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res; 2007 Feb 1;13(3):844-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor suppressor gene TP53 is located at 17p13.
  • TP53-mutant tumors were significantly larger than wild-type TP53 tumors (median tumor weight: 640 versus 185 g; P=0.02), were associated with a more advanced stage of tumor progression (MacFarlane stage IV; P=0.01), and had a shorter disease-free survival (P=0.03).
  • CONCLUSIONS: The finding that only a minority of adrenocortical tumors with 17p13 LOH had either a VNTR1 LOH or a TP53 mutation indicates that TP53 might not be the only or major tumor suppressor gene at 17p13 involved in adrenocortical cancer progression.
  • We suggest that a genetic instability of the 17p13 region, occurring early in adrenocortical cancer development, involves various genes located in this region.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Chromosomes, Human, Pair 17. Genes, p53. Loss of Heterozygosity. Minisatellite Repeats / genetics. Mutation
  • [MeSH-minor] Adult. Alleles. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Neoplasm / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17289876.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  •  go-up   go-down


98. Cantarovich D, Vistoli F, Soulillou JP: Immunosuppression minimization in kidney transplantation. Front Biosci; 2008;13:1413-32
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kidney transplantation is considered the best treatment for patients with end-stage renal failure, even in extreme age-groups.
  • This chronic, somewhat unselected, inhibition of the host immune system may induce complications, such as cancer and infection, that could counterbalance the benefits achieved by the transplant.
  • [MeSH-major] Adrenal Cortex Hormones / administration & dosage. Immunosuppressive Agents / therapeutic use. Kidney Transplantation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981639.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antibodies, Monoclonal; 0 / Calcineurin Inhibitors; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; WM0HAQ4WNM / Tacrolimus
  • [Number-of-references] 170
  •  go-up   go-down


99. Puthenparambil J, Lechner K, Kornek G: Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: A critical analysis of 52 cases reported in the literature. Wien Klin Wochenschr; 2010 Apr;122(7-8):229-36
Genetic Alliance. consumer health - Autoimmune Hemolytic Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that AIHA may occur prior to, concurrent with cancer or well after end of treatment, either as a sign of recurrence or in complete remission of the cancer.
  • AIHA occurred in almost all types of cancers, but it was relatively more common in renal cell cancer and Kaposi sarcoma compared to other cancers.
  • In early stage cancers, in particular in renal cell cancers, curative resection of the cancers led to complete, often sustained remission of AIHA within a short time in a number of patients.
  • Resection of the tumor had also beneficial effects in some metastatic cancers.
  • Patients who had a response to resection of the tumor were often refractory to steroid treatment before surgery, while some responses to steroids were observed in patients with metastatic cancer.
  • The study of cancer patients with autoimmune diseases may provide important insights into the biology of tumors.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / diagnosis. Neoplasms / diagnosis. Paraneoplastic Syndromes / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Autoantibodies / blood. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / immunology. Carcinoma, Renal Cell / surgery. Drug Resistance. Erythrocytes / immunology. Female. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / immunology. Kidney Neoplasms / surgery. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / immunology. Neoplasm Recurrence, Local / surgery. Prognosis. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / immunology. Sarcoma, Kaposi / surgery

  • Genetic Alliance. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Wien Klin Wochenschr. 2010 Apr;122(7-8):192-3 [20503016.001]
  • (PMID = 20503022.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Autoantibodies
  • [Number-of-references] 68
  •  go-up   go-down


100. Fujimaki T: Surgical treatment of brain metastasis. Int J Clin Oncol; 2005 Apr;10(2):74-80
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment modalities for brain metastasis or metastatic brain tumor include surgery, conventional irradiation, stereotactic radiosurgery (SRS), chemotherapy, and supportive care with corticosteroid.
  • Thus, although brain metastasis invariably indicates a stage 4 cancer, some patients can benefit from surgery.
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Combined Modality Therapy. Decision Making. Humans. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864691.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down






Advertisement